{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:20:28Z","timestamp":1789147228551,"version":"build-2803163510"},"reference-count":237,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:00:00Z","timestamp":1625875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:00:00Z","timestamp":1625875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"DAICENTER"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer is one of the lethal diseases that arise due to the molecular alterations in the cell. One of those alterations associated with cancer corresponds to differential expression of Farnesoid X receptor (FXR), a nuclear receptor regulating bile, cholesterol homeostasis, lipid, and glucose metabolism. FXR is known to regulate several diseases, including cancer and cardiovascular diseases, the two highly reported causes of mortality globally. Recent studies have shown the association of FXR overexpression with cancer development and progression in different types of cancers of breast, lung, pancreas, and oesophagus. It has also been associated with tissue-specific and cell-specific roles in various cancers. It has been shown to modulate several cell-signalling pathways such as EGFR\/ERK, NF-\u03baB, p38\/MAPK, PI3K\/AKT, Wnt\/\u03b2-catenin, and JAK\/STAT along with their targets such as caspases, MMPs, cyclins; tumour suppressor proteins like p53, C\/EBP\u03b2, and p-Rb; various cytokines; EMT markers; and many more. Therefore, FXR has high potential as novel biomarkers for the diagnosis, prognosis, and therapy of cancer. Thus, the present review focuses on the diverse role of FXR in different cancers and its agonists and antagonists.<\/jats:p>","DOI":"10.1186\/s43556-021-00035-2","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T23:20:18Z","timestamp":1625872818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer"],"prefix":"10.1186","volume":"2","author":[{"given":"Sosmitha","family":"Girisa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahu","family":"Henamayee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dey","family":"Parama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajaikumar B.","family":"Kunnumakkara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,10]]},"reference":[{"issue":"9","key":"35_CR1","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s11095-008-9661-9","volume":"25","author":"P Anand","year":"2008","unstructured":"Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008;25(9):2097\u2013116. https:\/\/doi.org\/10.1007\/s11095-008-9661-9.","journal-title":"Pharm Res"},{"issue":"13","key":"35_CR2","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.phymed.2015.08.015","volume":"22","author":"G Padmavathi","year":"2015","unstructured":"Padmavathi G, Rathnakaram SR, Monisha J, Bordoloi D, Roy NK, Kunnumakkara AB. Potential of butein, a tetrahydroxychalcone to obliterate cancer. Phytomedicine. 2015;22(13):1163\u201371. https:\/\/doi.org\/10.1016\/j.phymed.2015.08.015.","journal-title":"Phytomedicine."},{"issue":"1","key":"35_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/1574892810666151020101706","volume":"11","author":"D Bordoloi","year":"2016","unstructured":"Bordoloi D, Roy NK, Monisha J, Padmavathi G, Kunnumakkara AB. Multi-targeted agents in cancer cell chemosensitization: what we learnt from curcumin thus far. Recent Pat Anticancer Drug Discov. 2016;11(1):67\u201397. https:\/\/doi.org\/10.2174\/1574892810666151020101706.","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"27","key":"35_CR4","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.2174\/1381612822666160609110231","volume":"22","author":"J Monisha","year":"2016","unstructured":"Monisha J, Padmavathi G, Roy NK, Deka A, Bordoloi D, Anip A, et al. NF-\u03baB blockers gifted by mother nature: prospectives in cancer cell chemosensitization. Curr Pharm Des. 2016;22(27):4173\u2013200. https:\/\/doi.org\/10.2174\/1381612822666160609110231.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"35_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2016.04.017","volume":"377","author":"NK Roy","year":"2016","unstructured":"Roy NK, Deka A, Bordoloi D, Mishra S, Kumar AP, Sethi G, et al. The potential role of boswellic acids in cancer prevention and treatment. Cancer Lett. 2016;377(1):74\u201386. https:\/\/doi.org\/10.1016\/j.canlet.2016.04.017.","journal-title":"Cancer Lett"},{"key":"35_CR6","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3389\/fphar.2018.00686","volume":"9","author":"AB Kunnumakkara","year":"2018","unstructured":"Kunnumakkara AB, Banik K, Bordoloi D, Harsha C, Sailo BL, Padmavathi G, et al. Googling the guggul (Commiphora and Boswellia) for prevention of chronic diseases. Front Pharmacol. 2018;9:686. https:\/\/doi.org\/10.3389\/fphar.2018.00686.","journal-title":"Front Pharmacol"},{"key":"35_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1142\/9789813208575_0002","volume-title":"Cancer cell chemoresistance: a prime obstacle in cancer therapy. Cancer cell Chemoresistance and Chemosensitization","author":"J Monisha","year":"2018","unstructured":"Monisha J, Jaiswal A, Banik K, Choudhary H, Singh AK, Bordoloi D, et al. Cancer cell chemoresistance: a prime obstacle in cancer therapy. Cancer cell Chemoresistance and Chemosensitization. Singapore: World Scientific; 2018. p. 15\u201349."},{"key":"35_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.phrs.2018.02.017","volume":"130","author":"BL Sailo","year":"2018","unstructured":"Sailo BL, Banik K, Padmavathi G, Javadi M, Bordoloi D, Kunnumakkara AB. Tocotrienols: the promising analogues of vitamin E for cancer therapeutics. Pharmacol Res. 2018;130:259\u201372. https:\/\/doi.org\/10.1016\/j.phrs.2018.02.017.","journal-title":"Pharmacol Res"},{"key":"35_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.canlet.2017.12.014","volume":"416","author":"K Banik","year":"2018","unstructured":"Banik K, Harsha C, Bordoloi D, Lalduhsaki Sailo B, Sethi G, Leong HC, et al. Therapeutic potential of gambogic acid, a caged xanthone, to target cancer. Cancer Lett. 2018;416:75\u201386. https:\/\/doi.org\/10.1016\/j.canlet.2017.12.014.","journal-title":"Cancer Lett"},{"issue":"17","key":"35_CR10","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.3390\/ijms20174101","volume":"20","author":"NK Roy","year":"2019","unstructured":"Roy NK, Parama D, Banik K, Bordoloi D, Devi AK, Thakur KK, et al. An update on pharmacological potential of boswellic acids against chronic diseases. Int J Mol Sci. 2019;20(17):4101. https:\/\/doi.org\/10.3390\/ijms20174101.","journal-title":"Int J Mol Sci"},{"key":"35_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jff.2018.12.020","volume":"53","author":"YP Singh","year":"2019","unstructured":"Singh YP, Girisa S, Banik K, Ghosh S, Swathi P, Deka M, et al. Potential application of zerumbone in the prevention and therapy of chronic human diseases. J Funct Foods. 2019;53:248\u201358. https:\/\/doi.org\/10.1016\/j.jff.2018.12.020.","journal-title":"J Funct Foods"},{"issue":"20","key":"35_CR12","doi-asserted-by":"publisher","first-page":"30150","DOI":"10.1016\/j.semcancer.2020.06.014","volume":"S1044-579X","author":"E Khatoon","year":"2020","unstructured":"Khatoon E, Banik K, Harsha C, Sailo BL, Thakur KK, Khwairakpam AD, et al. Phytochemicals in cancer cell chemosensitization: current knowledge and future perspectives. Semin Cancer Biol. 2020;S1044-579X(20):30150\u20134. https:\/\/doi.org\/10.1016\/j.semcancer.2020.06.014.","journal-title":"Semin Cancer Biol"},{"key":"35_CR13","doi-asserted-by":"publisher","first-page":"118814","DOI":"10.1016\/j.lfs.2020.118814","volume":"267","author":"SA Ahmed","year":"2020","unstructured":"Ahmed SA, Parama D, Daimari E, Girisa S, Banik K, Harsha C, et al. Rationalizing the therapeutic potential of apigenin against cancer. Life Sci. 2020;267:118814. https:\/\/doi.org\/10.1016\/j.lfs.2020.118814.","journal-title":"Life Sci"},{"key":"35_CR14","doi-asserted-by":"publisher","unstructured":"Daimary UD, Parama D, Rana V, Banik K, Kumar A, Harsha C, et al. Emerging roles of cardamonin, a multitargeted nutraceutical in the prevention and treatment of chronic diseases. Curr Res Pharmacol Drug Discov:100008. https:\/\/doi.org\/10.1016\/j.crphar.2020.100008.","DOI":"10.1016\/j.crphar.2020.100008"},{"issue":"8","key":"35_CR15","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pi\u00f1eros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941\u201353. https:\/\/doi.org\/10.1002\/ijc.31937.","journal-title":"Int J Cancer"},{"issue":"10","key":"35_CR16","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3390\/molecules25102278","volume":"25","author":"S Henamayee","year":"2020","unstructured":"Henamayee S, Banik K, Sailo BL, Shabnam B, Harsha C, Srilakshmi S, et al. Therapeutic emergence of rhein as a potential anticancer drug: a review of its molecular targets and anticancer properties. Molecules. 2020;25(10):2278. https:\/\/doi.org\/10.3390\/molecules25102278.","journal-title":"Molecules."},{"issue":"4","key":"35_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jcrpr.2017.07.001","volume":"4","author":"SH Hassanpour","year":"2017","unstructured":"Hassanpour SH, Dehghani M. Review of cancer from perspective of molecular. J Cancer Res Pract. 2017;4(4):127\u20139. https:\/\/doi.org\/10.1016\/j.jcrpr.2017.07.001.","journal-title":"J Cancer Res Pract"},{"issue":"8","key":"35_CR18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1177\/1535370219839163","volume":"244","author":"AB Kunnumakkara","year":"2019","unstructured":"Kunnumakkara AB, Bordoloi D, Sailo BL, Roy NK, Thakur KK, Banik K, et al. Cancer drug development: the missing links. Exp Biol Med (Maywood). 2019;244(8):663\u201389. https:\/\/doi.org\/10.1177\/1535370219839163.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"1","key":"35_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00109-019-01863-0","volume":"98","author":"AD Khwairakpam","year":"2020","unstructured":"Khwairakpam AD, Banik K, Girisa S, Shabnam B, Shakibaei M, Fan L, et al. The vital role of ATP citrate lyase in chronic diseases. J Mol Med (Berl). 2020;98(1):71\u201395. https:\/\/doi.org\/10.1007\/s00109-019-01863-0.","journal-title":"J Mol Med (Berl)"},{"key":"35_CR20","first-page":"1","volume-title":"Fusion genes and Cancer","author":"NK Roy","year":"2017","unstructured":"Roy NK, Bordoloi D, Monisha J, Anip A, Padmavathi G, Kunnumakkara AB. Cancer- an overview and molecular alterations in cancer. In: Fusion genes and Cancer; 2017. p. 1\u201315."},{"issue":"11","key":"35_CR21","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/cr.2008.289","volume":"18","author":"YD Wang","year":"2008","unstructured":"Wang YD, Chen WD, Moore DD, Huang W. FXR: a metabolic regulator and cell protector. Cell Res. 2008;18(11):1087\u201395. https:\/\/doi.org\/10.1038\/cr.2008.289.","journal-title":"Cell Res"},{"issue":"6","key":"35_CR22","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1158\/2326-6066.CIR-17-0672","volume":"7","author":"W You","year":"2019","unstructured":"You W, Li L, Sun D, Liu X, Xia Z, Xue S, et al. Farnesoid X receptor constructs an immunosuppressive microenvironment and sensitizes FXRhighPD-L1low NSCLC to anti-PD-1 immunotherapy. Cancer Immunol Res. 2019;7(6):990\u20131000. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0672.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"35_CR23","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.3390\/ijms19071898","volume":"19","author":"M Kainuma","year":"2018","unstructured":"Kainuma M, Takada I, Makishima M, Sano K. Farnesoid X receptor activation enhances transforming growth factor \u03b2-induced epithelial-mesenchymal transition in hepatocellular carcinoma cells. Int J Mol Sci. 2018;19(7):1898. https:\/\/doi.org\/10.3390\/ijms19071898.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"35_CR24","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","volume":"81","author":"BM Forman","year":"1995","unstructured":"Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995;81(5):687\u201393. https:\/\/doi.org\/10.1016\/0092-8674(95)90530-8.","journal-title":"Cell."},{"issue":"2","key":"35_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1006\/taap.1999.8869","volume":"163","author":"WR Howard","year":"2000","unstructured":"Howard WR, Pospisil JA, Njolito E, Noonan DJ. Catabolites of cholesterol synthesis pathways and forskolin as activators of the farnesoid X-activated nuclear receptor. Toxicol Appl Pharmacol. 2000;163(2):195\u2013202. https:\/\/doi.org\/10.1006\/taap.1999.8869.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"35_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2009.05.015","volume":"287","author":"JH Joo","year":"2010","unstructured":"Joo JH, Jetten AM. Molecular mechanisms involved in farnesol-induced apoptosis. Cancer Lett. 2010;287(2):123\u201335. https:\/\/doi.org\/10.1016\/j.canlet.2009.05.015.","journal-title":"Cancer Lett"},{"issue":"3","key":"35_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000371670","volume":"33","author":"SA Kliewer","year":"2015","unstructured":"Kliewer SA, Mangelsdorf DJ. Bile acids as hormones: the FXR-FGF15\/19 pathway. Dig Dis. 2015;33(3):327\u201331. https:\/\/doi.org\/10.1159\/000371670.","journal-title":"Dig Dis"},{"issue":"5418","key":"35_CR28","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","volume":"284","author":"M Makishima","year":"1999","unstructured":"Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284(5418):1362\u20135. https:\/\/doi.org\/10.1126\/science.284.5418.1362.","journal-title":"Science."},{"issue":"5418","key":"35_CR29","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","volume":"284","author":"DJ Parks","year":"1999","unstructured":"Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999;284(5418):1365\u20138. https:\/\/doi.org\/10.1126\/science.284.5418.1365.","journal-title":"Science."},{"issue":"5","key":"35_CR30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/s1097-2765(00)80348-2","volume":"3","author":"H Wang","year":"1999","unstructured":"Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR. Mol Cell. 1999;3(5):543\u201353. https:\/\/doi.org\/10.1016\/s1097-2765(00)80348-2.","journal-title":"Mol Cell"},{"issue":"1","key":"35_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/s1050-1738(00)00043-8","volume":"10","author":"H Tu","year":"2000","unstructured":"Tu H, Okamoto AY, Shan B. FXR, a bile acid receptor and biological sensor. Trends Cardiovasc Med. 2000;10(1):30\u20135. https:\/\/doi.org\/10.1016\/s1050-1738(00)00043-8.","journal-title":"Trends Cardiovasc Med"},{"issue":"1","key":"35_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00010.2008","volume":"89","author":"P Lefebvre","year":"2009","unstructured":"Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89(1):147\u201391. https:\/\/doi.org\/10.1152\/physrev.00010.2008.","journal-title":"Physiol Rev"},{"key":"35_CR33","doi-asserted-by":"publisher","unstructured":"Wang C, Zhu C, Shao L, Ye J, Shen Y, Ren Y. Role of bile acids in dysbiosis and treatment of nonalcoholic fatty liver disease. Mediat Inflamm. 2019;7659509. https:\/\/doi.org\/10.1155\/2019\/7659509.","DOI":"10.1155\/2019\/7659509"},{"issue":"11","key":"35_CR34","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.bbalip.2012.07.004","volume":"1821","author":"DA Hollman","year":"2012","unstructured":"Hollman DA, Milona A, van Erpecum KJ, van Mil SW. Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim Biophys Acta. 2012;1821(11):1443\u201352. https:\/\/doi.org\/10.1016\/j.bbalip.2012.07.004.","journal-title":"Biochim Biophys Acta"},{"issue":"1\u20134","key":"35_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000149779","volume":"22","author":"H Shen","year":"2008","unstructured":"Shen H, Zhang Y, Ding H, Wang X, Chen L, Jiang H, et al. Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter. Cell Physiol Biochem. 2008;22(1\u20134):1\u201314. https:\/\/doi.org\/10.1159\/000149779.","journal-title":"Cell Physiol Biochem"},{"issue":"2","key":"35_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1124\/mol.116.106617","volume":"91","author":"R Sun","year":"2017","unstructured":"Sun R, Yang N, Kong B, Cao B, Feng D, Yu X, et al. Orally administered berberine modulates hepatic lipid metabolism by altering microbial bile acid metabolism and the intestinal fxr signaling pathway. Mol Pharmacol. 2017;91(2):110\u201322. https:\/\/doi.org\/10.1124\/mol.116.106617.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"35_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.bbalip.2014.08.005","volume":"1851","author":"RM Gadaleta","year":"2015","unstructured":"Gadaleta RM, Cariello M, Sabb\u00e0 C, Moschetta A. Tissue-specific actions of FXR in metabolism and cancer. Biochim Biophys Acta. 2015;1851(1):30\u20139. https:\/\/doi.org\/10.1016\/j.bbalip.2014.08.005.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"35_CR38","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1172\/JCI25604","volume":"116","author":"K Ma","year":"2006","unstructured":"Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest. 2006;116(4):1102\u20139. https:\/\/doi.org\/10.1172\/JCI25604.","journal-title":"J Clin Invest"},{"issue":"4","key":"35_CR39","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1194\/jlr.M001602","volume":"51","author":"S Cipriani","year":"2010","unstructured":"Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa\/fa) obese rats. J Lipid Res. 2010;51(4):771\u201384. https:\/\/doi.org\/10.1194\/jlr.M001602.","journal-title":"J Lipid Res"},{"issue":"10","key":"35_CR40","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1172\/JCI21025","volume":"113","author":"M Watanabe","year":"2004","unstructured":"Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest. 2004;113(10):1408\u201318. https:\/\/doi.org\/10.1172\/JCI21025.","journal-title":"J Clin Invest"},{"issue":"7","key":"35_CR41","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.3390\/ijms19072069","volume":"19","author":"CY Han","year":"2018","unstructured":"Han CY. Update on FXR biology: promising therapeutic target? Int J Mol Sci. 2018;19(7):2069. https:\/\/doi.org\/10.3390\/ijms19072069.","journal-title":"Int J Mol Sci"},{"key":"35_CR42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4103\/2394-4722.164288","volume":"2","author":"G Xie","year":"2016","unstructured":"Xie G, Raufman J-P. The farnesoid X receptor and colon cancer. J Cancer Metastasis Treat. 2016;2:24\u20138. https:\/\/doi.org\/10.4103\/2394-4722.164288.","journal-title":"J Cancer Metastasis Treat"},{"issue":"5","key":"35_CR43","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/hep.22519","volume":"48","author":"YD Wang","year":"2008","unstructured":"Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008;48(5):1632\u201343. https:\/\/doi.org\/10.1002\/hep.22519.","journal-title":"Hepatology."},{"issue":"7","key":"35_CR44","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.molmed.2007.06.001","volume":"13","author":"S Fiorucci","year":"2007","unstructured":"Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med. 2007;13(7):298\u2013309. https:\/\/doi.org\/10.1016\/j.molmed.2007.06.001.","journal-title":"Trends Mol Med"},{"issue":"4","key":"35_CR45","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/s1097-2765(03)00104-7","volume":"11","author":"M Downes","year":"2003","unstructured":"Downes M, Verdecia MA, Roecker AJ, Hughes R, Hogenesch JB, Kast-Woelbern HR, et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell. 2003;11(4):1079\u201392. https:\/\/doi.org\/10.1016\/s1097-2765(03)00104-7.","journal-title":"Mol Cell"},{"issue":"1\u20132","key":"35_CR46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/s0378-1119(02)00557-7","volume":"290","author":"RM Huber","year":"2002","unstructured":"Huber RM, Murphy K, Miao B, Link JR, Cunningham MR, Rupar MJ, et al. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene. 2002;290(1\u20132):35\u201343. https:\/\/doi.org\/10.1016\/s0378-1119(02)00557-7.","journal-title":"Gene."},{"issue":"1","key":"35_CR47","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1074\/jbc.M209505200","volume":"278","author":"Y Zhang","year":"2003","unstructured":"Zhang Y, Kast-Woelbern HR, Edwards PA. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem. 2003;278(1):104\u201310. https:\/\/doi.org\/10.1074\/jbc.M209505200.","journal-title":"J Biol Chem"},{"issue":"11","key":"35_CR48","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.tem.2011.07.002","volume":"22","author":"JS Teodoro","year":"2011","unstructured":"Teodoro JS, Rolo AP, Palmeira CM. Hepatic FXR: key regulator of whole-body energy metabolism. Trends Endocrinol Metab. 2011;22(11):458\u201366. https:\/\/doi.org\/10.1016\/j.tem.2011.07.002.","journal-title":"Trends Endocrinol Metab"},{"issue":"10","key":"35_CR49","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.tibs.2006.08.002","volume":"31","author":"FY Lee","year":"2006","unstructured":"Lee FY, Lee H, Hubbert ML, Edwards PA, Zhang Y. FXR, a multipurpose nuclear receptor. Trends Biochem Sci. 2006;31(10):572\u201380. https:\/\/doi.org\/10.1016\/j.tibs.2006.08.002.","journal-title":"Trends Biochem Sci"},{"key":"35_CR50","doi-asserted-by":"publisher","first-page":"14086","DOI":"10.1038\/srep14086","volume":"5","author":"IT Bijsmans","year":"2015","unstructured":"Bijsmans IT, Guercini C, Ramos Pittol JM, Omta W, Milona A, Lelieveld D, et al. The glucocorticoid mometasone furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression. Sci Rep. 2015 Sep 15;5:14086. https:\/\/doi.org\/10.1038\/srep14086.","journal-title":"Sci Rep"},{"issue":"2","key":"35_CR51","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1210\/me.2014-1225","volume":"29","author":"YD Wang","year":"2015","unstructured":"Wang YD, Chen WD, Li C, Guo C, Li Y, Qi H, et al. Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3. Mol Endocrinol. 2015;29(2):322\u201331. https:\/\/doi.org\/10.1210\/me.2014-1225.","journal-title":"Mol Endocrinol"},{"issue":"3","key":"35_CR52","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/hep.1840130331","volume":"13","author":"ZR Vlahcevic","year":"1991","unstructured":"Vlahcevic ZR, Heuman DM, Hylemon PB. Regulation of bile acid synthesis. Hepatology. 1991;13(3):590\u2013600. https:\/\/doi.org\/10.1002\/hep.1840130331.","journal-title":"Hepatology."},{"issue":"2","key":"35_CR53","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2174\/156652407780059168","volume":"7","author":"M Norlin","year":"2007","unstructured":"Norlin M, Wikvall K. Enzymes in the conversion of cholesterol into bile acids. Curr Mol Med. 2007;7(2):199\u2013218. https:\/\/doi.org\/10.2174\/156652407780059168.","journal-title":"Curr Mol Med"},{"issue":"3","key":"35_CR54","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1210\/me.2002-0246","volume":"17","author":"B Goodwin","year":"2003","unstructured":"Goodwin B, Watson MA, Kim H, Miao J, Kemper JK, Kliewer SA. Differential regulation of rat and human CYP7A1 by the nuclear oxysterol receptor liver X receptor-alpha. Mol Endocrinol. 2003;17(3):386\u201394. https:\/\/doi.org\/10.1210\/me.2002-0246.","journal-title":"Mol Endocrinol"},{"issue":"3","key":"35_CR55","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/s1097-2765(00)00051-4","volume":"6","author":"B Goodwin","year":"2000","unstructured":"Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000;6(3):517\u201326. https:\/\/doi.org\/10.1016\/s1097-2765(00)00051-4.","journal-title":"Mol Cell"},{"issue":"10","key":"35_CR56","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.2337\/db06-1642","volume":"56","author":"T Jiang","year":"2007","unstructured":"Jiang T, Wang XX, Scherzer P, Wilson P, Tallman J, Takahashi H, et al. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes. 2007;56(10):2485\u201393. https:\/\/doi.org\/10.2337\/db06-1642.","journal-title":"Diabetes."},{"issue":"4","key":"35_CR57","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s12072-010-9202-6","volume":"4","author":"ZX Yang","year":"2010","unstructured":"Yang ZX, Shen W, Sun H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol Int. 2010;4(4):741\u20138. https:\/\/doi.org\/10.1007\/s12072-010-9202-6.","journal-title":"Hepatol Int"},{"issue":"5","key":"35_CR58","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.apsb.2016.07.008","volume":"6","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Liu H, Zhang M, Guo GL. Fatty liver diseases, bile acids, and FXR. Acta Pharm Sin B. 2016;6(5):409\u201312. https:\/\/doi.org\/10.1016\/j.apsb.2016.07.008.","journal-title":"Acta Pharm Sin B"},{"issue":"10","key":"35_CR59","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1161\/01.ATV.0000178994.21828.a7","volume":"25","author":"T Claudel","year":"2005","unstructured":"Claudel T, Staels B, Kuipers F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol. 2005;25(10):2020\u201330. https:\/\/doi.org\/10.1161\/01.ATV.0000178994.21828.a7.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"35_CR60","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrm3312","volume":"13","author":"AC Calkin","year":"2012","unstructured":"Calkin AC, Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol. 2012;13(4):213\u201324. https:\/\/doi.org\/10.1038\/nrm3312.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"35_CR61","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.febslet.2007.11.015","volume":"582","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, Edwards PA. FXR signaling in metabolic disease. FEBS Lett. 2008;582(1):10\u20138. https:\/\/doi.org\/10.1016\/j.febslet.2007.11.015.","journal-title":"FEBS Lett"},{"issue":"8","key":"35_CR62","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/j.cellsig.2012.04.015","volume":"24","author":"Z Xu","year":"2012","unstructured":"Xu Z, Huang G, Gong W, Zhou P, Zhao Y, Zhang Y, et al. FXR ligands protect against hepatocellular inflammation via SOCS3 induction. Cell Signal. 2012;24(8):1658\u201364. https:\/\/doi.org\/10.1016\/j.cellsig.2012.04.015.","journal-title":"Cell Signal"},{"key":"35_CR63","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3389\/fmed.2020.00544","volume":"7","author":"M Stofan","year":"2020","unstructured":"Stofan M, Guo GL. Bile acids and FXR: novel targets for liver diseases. Front Med (Lausanne). 2020;7:544. https:\/\/doi.org\/10.3389\/fmed.2020.00544.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"35_CR64","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/gut.2010.212159","volume":"60","author":"RM Gadaleta","year":"2011","unstructured":"Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011;60(4):463\u201372. https:\/\/doi.org\/10.1136\/gut.2010.212159.","journal-title":"Gut."},{"issue":"12","key":"35_CR65","doi-asserted-by":"publisher","first-page":"5112","DOI":"10.1182\/blood-2007-01-067256","volume":"109","author":"AB Kunnumakkara","year":"2007","unstructured":"Kunnumakkara AB, Nair AS, Ahn KS, Pandey MK, Yi Z, Liu M, et al. Gossypin, a pentahydroxy glucosyl flavone, inhibits the transforming growth factor beta-activated kinase-1-mediated NF-kappaB activation pathway, leading to potentiation of apoptosis, suppression of invasion, and abrogation of osteoclastogenesis. Blood. 2007;109(12):5112\u201321. https:\/\/doi.org\/10.1182\/blood-2007-01-067256.","journal-title":"Blood."},{"issue":"12","key":"35_CR66","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.3390\/nu11122904","volume":"11","author":"C Buhrmann","year":"2019","unstructured":"Buhrmann C, Popper B, Kunnumakkara AB, Aggarwal BB, Shakibaei M. Evidence that Calebin a, a component of Curcuma Longa suppresses NF-\u03baB mediated proliferation, invasion and metastasis of human colorectal cancer induced by TNF-\u03b2 (Lymphotoxin). Nutrients. 2019;11(12):2904. https:\/\/doi.org\/10.3390\/nu11122904.","journal-title":"Nutrients."},{"issue":"3","key":"35_CR67","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/hep.30513","volume":"70","author":"JM Ferrell","year":"2019","unstructured":"Ferrell JM, Pathak P, Boehme S, Gilliland T, Chiang JY. Deficiency of both farnesoid x receptor and takeda g protein\u2013coupled receptor 5 exacerbated liver fibrosis in mice. Hepatology. 2019;70(3):955\u201370. https:\/\/doi.org\/10.1002\/hep.30513.","journal-title":"Hepatology."},{"key":"35_CR68","doi-asserted-by":"publisher","unstructured":"Jung H, Chen J, Hu X, Sun H, Wu SY, Chiang CM, et al. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination. JCI Insight. 2020:e141640. https:\/\/doi.org\/10.1172\/jci.insight.141640.","DOI":"10.1172\/jci.insight.141640"},{"key":"35_CR69","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jsbmb.2017.01.010","volume":"168","author":"P Comeglio","year":"2017","unstructured":"Comeglio P, Filippi S, Sarchielli E, Morelli A, Cellai I, Corcetto F, et al. Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis. J Steroid Biochem Mol Biol. 2017;168:26\u201337. https:\/\/doi.org\/10.1016\/j.jsbmb.2017.01.010.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"1","key":"35_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep33453","volume":"6","author":"L Verbeke","year":"2016","unstructured":"Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Klein S, Vander Elst I, et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep. 2016;6(1):1\u20132. https:\/\/doi.org\/10.1038\/srep33453.","journal-title":"Sci Rep"},{"issue":"8","key":"35_CR71","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s40618-019-1009-2","volume":"42","author":"P Comeglio","year":"2019","unstructured":"Comeglio P, Filippi S, Sarchielli E, Morelli A, Cellai I, Corno C, et al. Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model. J Endocrinol Investig. 2019;42(8):951\u201365. https:\/\/doi.org\/10.1007\/s40618-019-1009-2.","journal-title":"J Endocrinol Investig"},{"key":"35_CR72","doi-asserted-by":"publisher","first-page":"37234","DOI":"10.1038\/srep37234","volume":"6","author":"K Zhao","year":"2016","unstructured":"Zhao K, He J, Zhang Y, Xu Z, Xiong H, Gong R, et al. Activation of FXR protects against renal fibrosis via suppressing Smad3 expression. Sci Rep. 2016;6:37234. https:\/\/doi.org\/10.1038\/srep37234.","journal-title":"Sci Rep"},{"issue":"10","key":"35_CR73","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1161\/01.ATV.0000235697.35431.05","volume":"26","author":"Y Zhang","year":"2006","unstructured":"Zhang Y, Wang X, Vales C, Lee FY, Lee H, Lusis AJ, et al. FXR deficiency causes reduced atherosclerosis in Ldlr\u2212\/\u2212 mice. Arterioscler Thromb Vasc Biol. 2006;26(10):2316\u201321. https:\/\/doi.org\/10.1161\/01.ATV.0000235697.35431.05.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"35_CR74","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1111\/j.1572-0241.2008.01908.x","volume":"103","author":"A Capello","year":"2008","unstructured":"Capello A, Moons LM, Van de Winkel A, Siersema PD, van Dekken H, Kuipers EJ, et al. Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus. Am J Gastroenterol. 2008;103(6):1510\u20136. https:\/\/doi.org\/10.1111\/j.1572-0241.2008.01908.x.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"35_CR75","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.celrep.2013.10.030","volume":"5","author":"S Anakk","year":"2013","unstructured":"Anakk S, Bhosale M, Schmidt VA, Johnson RL, Finegold MJ, Moore DD. Bile acids activate YAP to promote liver carcinogenesis. Cell Rep. 2013;5(4):1060\u20139. https:\/\/doi.org\/10.1016\/j.celrep.2013.10.030.","journal-title":"Cell Rep"},{"issue":"4","key":"35_CR76","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.bbrc.2019.09.033","volume":"519","author":"M Hotta","year":"2019","unstructured":"Hotta M, Sakatani T, Ishino K, Wada R, Kudo M, Yokoyama Y, et al. Farnesoid X receptor induces cell death and sensitizes to TRAIL- induced inhibition of growth in colorectal cancer cells through the up-regulation of death receptor 5. Biochem Biophys Res Commun. 2019;519(4):824\u201331. https:\/\/doi.org\/10.1016\/j.bbrc.2019.09.033.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"35_CR77","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.3892\/or.2018.6636","volume":"40","author":"P Qiao","year":"2018","unstructured":"Qiao P, Li S, Zhang H, Yao L, Wang F. Farnesoid X receptor inhibits proliferation of human colorectal cancer cells via the miR-135A1\/CCNG2 signaling pathway. Oncol Rep. 2018;40(4):2067\u201378. https:\/\/doi.org\/10.3892\/or.2018.6636.","journal-title":"Oncol Rep"},{"issue":"1","key":"35_CR78","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/hep.20776","volume":"42","author":"BD Juran","year":"2005","unstructured":"Juran BD, Lazaridis KN. Is the FXR the fix for cholesterol gallstone disease? Hepatology. 2005;42(1):218\u201321. https:\/\/doi.org\/10.1002\/hep.20776.","journal-title":"Hepatology."},{"key":"35_CR79","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S0076-6879(09)63040-8","volume":"463","author":"AR Farley","year":"2009","unstructured":"Farley AR, Link AJ. Identification and quantification of protein posttranslational modifications. Methods Enzymol. 2009;463:725\u201363. https:\/\/doi.org\/10.1016\/S0076-6879(09)63040-8.","journal-title":"Methods Enzymol"},{"key":"35_CR80","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/bs.mie.2016.10.017","volume":"586","author":"C Zhang","year":"2017","unstructured":"Zhang C, Liu Y. Retrieving quantitative information of histone ptms by mass spectrometry. Methods Enzymol. 2017;586:165\u201391. https:\/\/doi.org\/10.1016\/bs.mie.2016.10.017.","journal-title":"Methods Enzymol"},{"key":"35_CR81","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/bs.mie.2016.09.030","volume":"586","author":"A Hashiguchi","year":"2017","unstructured":"Hashiguchi A, Komatsu S. Posttranslational modifications and plant-environment interaction. Methods Enzymol. 2017;586:97\u2013113. https:\/\/doi.org\/10.1016\/bs.mie.2016.09.030.","journal-title":"Methods Enzymol"},{"issue":"4","key":"35_CR82","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3945\/an.114.005868","volume":"5","author":"DF Romagnolo","year":"2014","unstructured":"Romagnolo DF, Zempleni J, Selmin OI. Nuclear receptors and epigenetic regulation: opportunities for nutritional targeting and disease prevention. Adv Nutr. 2014;5(4):373\u201385. https:\/\/doi.org\/10.3945\/an.114.005868.","journal-title":"Adv Nutr"},{"issue":"2","key":"35_CR83","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1210\/en.2016-1577","volume":"158","author":"N Becares","year":"2017","unstructured":"Becares N, Gage MC, Pineda-Torra I. Posttranslational modifications of lipid-activated nuclear receptors: focus on metabolism. Endocrinology. 2017;158(2):213\u201325. https:\/\/doi.org\/10.1210\/en.2016-1577.","journal-title":"Endocrinology."},{"issue":"50","key":"35_CR84","doi-asserted-by":"publisher","first-page":"35086","DOI":"10.1074\/jbc.M803531200","volume":"283","author":"S Fang","year":"2008","unstructured":"Fang S, Tsang S, Jones R, Ponugoti B, Yoon H, Wu SY, et al. The p300 acetylase is critical for ligand-activated farnesoid X receptor (FXR) induction of SHP. J Biol Chem. 2008;283(50):35086\u201395. https:\/\/doi.org\/10.1074\/jbc.M803531200.","journal-title":"J Biol Chem"},{"issue":"1","key":"35_CR85","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.molcel.2007.07.032","volume":"28","author":"X Li","year":"2007","unstructured":"Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell. 2007;28(1):91\u2013106. https:\/\/doi.org\/10.1016\/j.molcel.2007.07.032.","journal-title":"Mol Cell"},{"issue":"5","key":"35_CR86","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.cmet.2009.09.009","volume":"10","author":"JK Kemper","year":"2009","unstructured":"Kemper JK, Xiao Z, Ponugoti B, Miao J, Fang S, Kanamaluru D, et al. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab. 2009;10(5):392\u2013404. https:\/\/doi.org\/10.1016\/j.cmet.2009.09.009.","journal-title":"Cell Metab"},{"issue":"5600","key":"35_CR87","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1126\/science.1075762","volume":"298","author":"G Manning","year":"2002","unstructured":"Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298(5600):1912\u201334. https:\/\/doi.org\/10.1126\/science.1075762.","journal-title":"Science."},{"issue":"11","key":"35_CR88","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1210\/me.2008-0092","volume":"22","author":"R Gineste","year":"2008","unstructured":"Gineste R, Sirvent A, Paumelle R, Helleboid S, Aquilina A, Darteil R, et al. Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. Mol Endocrinol. 2008;22(11):2433\u201347. https:\/\/doi.org\/10.1210\/me.2008-0092.","journal-title":"Mol Endocrinol"},{"issue":"8","key":"35_CR89","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.bbadis.2010.11.011","volume":"1812","author":"JK Kemper","year":"2011","unstructured":"Kemper JK. Regulation of FXR transcriptional activity in health and disease: emerging roles of FXR cofactors and post-translational modifications. Biochim Biophys Acta. 2011;1812(8):842\u201350. https:\/\/doi.org\/10.1016\/j.bbadis.2010.11.011.","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"35_CR90","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1210\/me.2016-1105","volume":"30","author":"T Hashiguchi","year":"2016","unstructured":"Hashiguchi T, Arakawa S, Takahashi S, Gonzalez FJ, Sueyoshi T, Negishi M. Phosphorylation of farnesoid X receptor at serine 154 links ligand activation with degradation. Mol Endocrinol. 2016;30(10):1070\u201380. https:\/\/doi.org\/10.1210\/me.2016-1105.","journal-title":"Mol Endocrinol"},{"issue":"3","key":"35_CR91","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/ng0398-219","volume":"18","author":"LN Bull","year":"1998","unstructured":"Bull LN, van Eijk MJ, Pawlikowska L, DeYoung JA, Juijn JA, Liao M, et al. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet. 1998;18(3):219\u201324. https:\/\/doi.org\/10.1038\/ng0398-219.","journal-title":"Nat Genet"},{"issue":"6","key":"35_CR92","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1002\/hep.22431","volume":"48","author":"T Frankenberg","year":"2008","unstructured":"Frankenberg T, Miloh T, Chen FY, Ananthanarayanan M, Sun AQ, Balasubramaniyan N, et al. The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor. Hepatology. 2008;48(6):1896\u2013905. https:\/\/doi.org\/10.1002\/hep.22431.","journal-title":"Hepatology."},{"issue":"3","key":"35_CR93","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1172\/JCI68815","volume":"124","author":"F Lien","year":"2014","unstructured":"Lien F, Berthier A, Bouchaert E, Gheeraert C, Alexandre J, Porez G, et al. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J Clin Invest. 2014;124(3):1037\u201351. https:\/\/doi.org\/10.1172\/JCI68815.","journal-title":"J Clin Invest"},{"key":"35_CR94","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3389\/fphar.2017.00260","volume":"8","author":"J Yang","year":"2017","unstructured":"Yang J, Sun L, Wang L, Hassan HM, Wang X, Hylemon PB, et al. Activation of Sirt1\/FXR signaling pathway attenuates triptolide-induced hepatotoxicity in rats. Front Pharmacol. 2017;8:260. https:\/\/doi.org\/10.3389\/fphar.2017.00260.","journal-title":"Front Pharmacol"},{"key":"35_CR95","doi-asserted-by":"publisher","first-page":"6705927","DOI":"10.1155\/2016\/6705927","volume":"2016","author":"B Suresh","year":"2016","unstructured":"Suresh B, Lee J, Kim KS, Ramakrishna S. The importance of ubiquitination and deubiquitination in cellular reprogramming. Stem Cells Int. 2016;2016:6705927. https:\/\/doi.org\/10.1155\/2016\/6705927.","journal-title":"Stem Cells Int"},{"issue":"2","key":"35_CR96","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.yexcr.2018.07.004","volume":"371","author":"Y Gao","year":"2018","unstructured":"Gao Y, Zhao Y, Yuan A, Xu L, Huang X, Su Y, et al. Effects of farnesoid-X-receptor SUMOylation mutation on myocardial ischemia\/reperfusion injury in mice. Exp Cell Res. 2018;371(2):301\u201310. https:\/\/doi.org\/10.1016\/j.yexcr.2018.07.004.","journal-title":"Exp Cell Res"},{"issue":"2","key":"35_CR97","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/cancers11020246","volume":"11","author":"BL Sailo","year":"2019","unstructured":"Sailo BL, Banik K, Girisa S, Bordoloi D, Fan L, Halim CE, et al. FBXW7 in cancer: what has been unraveled thus far? Cancers (Basel). 2019;11(2):246. https:\/\/doi.org\/10.3390\/cancers11020246.","journal-title":"Cancers (Basel)"},{"key":"35_CR98","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.biocel.2018.06.001","volume":"101","author":"MA Mansour","year":"2018","unstructured":"Mansour MA. Ubiquitination: friend and foe in cancer. Int J Biochem Cell Biol. 2018;101:80\u201393. https:\/\/doi.org\/10.1016\/j.biocel.2018.06.001.","journal-title":"Int J Biochem Cell Biol"},{"issue":"19","key":"35_CR99","doi-asserted-by":"publisher","first-page":"13850","DOI":"10.1074\/jbc.M112.443937","volume":"288","author":"N Balasubramaniyan","year":"2013","unstructured":"Balasubramaniyan N, Luo Y, Sun AQ, Suchy FJ. SUMOylation of the farnesoid X receptor (FXR) regulates the expression of FXR target genes. J Biol Chem. 2013;288(19):13850\u201362. https:\/\/doi.org\/10.1074\/jbc.M112.443937.","journal-title":"J Biol Chem"},{"issue":"3","key":"35_CR100","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/jmcb\/mjx009","volume":"9","author":"S Bilodeau","year":"2017","unstructured":"Bilodeau S, Caron V, Gagnon J, Kuftedjian A, Tremblay A. A CK2-RNF4 interplay coordinates non-canonical SUMOylation and degradation of nuclear receptor FXR. J Mol Cell Biol. 2017;9(3):195\u2013208. https:\/\/doi.org\/10.1093\/jmcb\/mjx009.","journal-title":"J Mol Cell Biol"},{"issue":"5","key":"35_CR101","doi-asserted-by":"publisher","first-page":"200054","DOI":"10.1098\/rsob.200054","volume":"10","author":"A Talamillo","year":"2020","unstructured":"Talamillo A, Ajuria L, Grillo M, Barroso-Gomila O, Mayor U, Barrio R. SUMOylation in the control of cholesterol homeostasis. Open Biol. 2020;10(5):200054. https:\/\/doi.org\/10.1098\/rsob.200054.","journal-title":"Open Biol"},{"key":"35_CR102","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fendo.2014.00230","volume":"5","author":"F Benhamed","year":"2015","unstructured":"Benhamed F, Filhoulaud G, Caron S, Lefebvre P, Staels B, Postic C. O-GlcNAcylation links ChREBP and FXR to glucose-sensing. Front Endocrinol (Lausanne). 2015;5:230. https:\/\/doi.org\/10.3389\/fendo.2014.00230.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"35_CR103","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s13018-019-1404-6","volume":"14","author":"B Wu","year":"2019","unstructured":"Wu B, Xing C, Tao J. Upregulation of microRNA-23b-3p induced by farnesoid X receptor regulates the proliferation and apoptosis of osteosarcoma cells. J Orthop Surg Res. 2019;14(1):398. https:\/\/doi.org\/10.1186\/s13018-019-1404-6.","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"35_CR104","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1186\/s12885-020-07106-7","volume":"20","author":"L Absil","year":"2020","unstructured":"Absil L, Journ\u00e9 F, Larsimont D, Body JJ, Tafforeau L, Nonclercq D. Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cells. BMC Cancer. 2020;20(1):640. https:\/\/doi.org\/10.1186\/s12885-020-07106-7.","journal-title":"BMC Cancer"},{"key":"35_CR105","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.canlet.2018.08.026","volume":"437","author":"I Barone","year":"2018","unstructured":"Barone I, Vircillo V, Giordano C, Gelsomino L, Gy\u0151rffy B, Tarallo R, et al. Activation of farnesoid X receptor impairs the tumor-promoting function of breast cancer-associated fibroblasts. Cancer Lett. 2018;437:89\u201399. https:\/\/doi.org\/10.1016\/j.canlet.2018.08.026.","journal-title":"Cancer Lett"},{"key":"35_CR106","doi-asserted-by":"publisher","first-page":"21782","DOI":"10.1038\/srep21782","volume":"6","author":"C Giordano","year":"2016","unstructured":"Giordano C, Barone I, Vircillo V, Panza S, Malivindi R, Gelsomino L, et al. Activated FXR inhibits leptin signaling and counteracts tumor-promoting activities of cancer-associated fibroblasts in breast malignancy. Sci Rep. 2016;6:21782. https:\/\/doi.org\/10.1038\/srep21782.","journal-title":"Sci Rep"},{"issue":"2","key":"35_CR107","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.canlet.2015.10.031","volume":"370","author":"N Alasmael","year":"2016","unstructured":"Alasmael N, Mohan R, Meira LB, Swales KE, Plant NJ. Activation of the farnesoid X-receptor in breast cancer cell lines results in cytotoxicity but not increased migration potential. Cancer Lett. 2016;370(2):250\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2015.10.031.","journal-title":"Cancer Lett"},{"issue":"7","key":"35_CR108","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1080\/01635581.2012.717679","volume":"64","author":"JP Vanden Heuvel","year":"2012","unstructured":"Vanden Heuvel JP, Belda BJ, Hannon DB, Kris-Etherton PM, Grieger JA, Zhang J, et al. Mechanistic examination of walnuts in prevention of breast cancer. Nutr Cancer. 2012;64(7):1078\u201386. https:\/\/doi.org\/10.1080\/01635581.2012.717679.","journal-title":"Nutr Cancer"},{"issue":"39","key":"35_CR109","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1038\/onc.2011.124","volume":"30","author":"C Giordano","year":"2011","unstructured":"Giordano C, Catalano S, Panza S, Vizza D, Barone I, Bonofiglio D, et al. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Oncogene. 2011;30(39):4129\u201340. https:\/\/doi.org\/10.1038\/onc.2011.124.","journal-title":"Oncogene."},{"issue":"3","key":"35_CR110","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10549-008-0094-2","volume":"115","author":"F Journe","year":"2009","unstructured":"Journe F, Durbecq V, Chaboteaux C, Rouas G, Laurent G, Nonclercq D, et al. Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients. Breast Cancer Res Treat. 2009;115(3):523\u201335. https:\/\/doi.org\/10.1007\/s10549-008-0094-2.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"35_CR111","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10549-007-9535-6","volume":"107","author":"F Journe","year":"2008","unstructured":"Journe F, Laurent G, Chaboteaux C, Nonclercq D, Durbecq V, Larsimont D, et al. Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation. Breast Cancer Res Treat. 2008;107(1):49\u201361. https:\/\/doi.org\/10.1007\/s10549-007-9535-6.","journal-title":"Breast Cancer Res Treat"},{"issue":"20","key":"35_CR112","doi-asserted-by":"publisher","first-page":"10120","DOI":"10.1158\/0008-5472.CAN-06-2399","volume":"66","author":"KE Swales","year":"2006","unstructured":"Swales KE, Korbonits M, Carpenter R, Walsh DT, Warner TD, Bishop-Bailey D. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res. 2006;66(20):10120\u20136. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2399.","journal-title":"Cancer Res"},{"issue":"4","key":"35_CR113","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1194\/jlr.M500473-JLR200","volume":"47","author":"J Silva","year":"2006","unstructured":"Silva J, Dasgupta S, Wang G, Krishnamurthy K, Ritter E, Bieberich E. Lipids isolated from bone induce the migration of human breast cancer cells. J Lipid Res. 2006;47(4):724\u201333. https:\/\/doi.org\/10.1194\/jlr.M500473-JLR200.","journal-title":"J Lipid Res"},{"issue":"23","key":"35_CR114","doi-asserted-by":"publisher","first-page":"34617","DOI":"10.18632\/oncotarget.8964","volume":"7","author":"W Wang","year":"2016","unstructured":"Wang W, Zhan M, Li Q, Chen W, Chu H, Huang Q, et al. FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression. Oncotarget. 2016;7(23):34617\u201329. https:\/\/doi.org\/10.18632\/oncotarget.8964.","journal-title":"Oncotarget"},{"issue":"1","key":"35_CR115","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.gene.2011.11.028","volume":"493","author":"XY Zhong","year":"2012","unstructured":"Zhong XY, Yu JH, Zhang WG, Wang ZD, Dong Q, Tai S, et al. MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression. Gene. 2012;493(1):44\u201351. https:\/\/doi.org\/10.1016\/j.gene.2011.11.028.","journal-title":"Gene."},{"issue":"1","key":"35_CR116","doi-asserted-by":"publisher","first-page":"e0210077","DOI":"10.1371\/journal.pone.0210077","volume":"14","author":"S Di Matteo","year":"2019","unstructured":"Di Matteo S, Nevi L, Costantini D, Overi D, Carpino G, Safarikia S, et al. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma. PLoS One. 2019;14(1):e0210077. https:\/\/doi.org\/10.1371\/journal.pone.0210077.","journal-title":"PLoS One"},{"issue":"4 Pt B","key":"35_CR117","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.bbadis.2017.08.016","volume":"1864","author":"O Erice","year":"2018","unstructured":"Erice O, Labiano I, Arbelaiz A, Santos-Laso A, Munoz-Garrido P, Jimenez-Ag\u00fcero R, et al. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression. Biochim Biophys Acta Mol basis Dis. 2018;1864(4 Pt B):1335\u201344. https:\/\/doi.org\/10.1016\/j.bbadis.2017.08.016.","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"key":"35_CR118","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1756-8722-4-41","volume":"4","author":"J Dai","year":"2011","unstructured":"Dai J, Wang H, Shi Y, Dong Y, Zhang Y, Wang J. Impact of bile acids on the growth of human cholangiocarcinoma via FXR. J Hematol Oncol. 2011;4:41. https:\/\/doi.org\/10.1186\/1756-8722-4-41.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"35_CR119","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000491715","volume":"48","author":"B Lv","year":"2018","unstructured":"Lv B, Ma L, Tang W, Huang P, Yang B, Wang L, et al. FXR acts as a metastasis suppressor in intrahepatic cholangiocarcinoma by inhibiting il-6-induced epithelial-mesenchymal transition. Cell Physiol Biochem. 2018;48(1):158\u201372. https:\/\/doi.org\/10.1159\/000491715.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"35_CR120","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3892\/ol.2020.11545","volume":"20","author":"J Mao","year":"2020","unstructured":"Mao J, Chen X, Wang C, Li W, Li J. Effects and mechanism of the bile (farnesoid X) receptor on the Wnt\/\u03b2-catenin signaling pathway in colon cancer. Oncol Lett. 2020;20(1):337\u201345. https:\/\/doi.org\/10.3892\/ol.2020.11545.","journal-title":"Oncol Lett"},{"issue":"21","key":"35_CR121","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.1074\/jbc.RA118.004361","volume":"294","author":"Z Peng","year":"2019","unstructured":"Peng Z, Chen J, Drachenberg CB, Raufman JP, Xie G. Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer. J Biol Chem. 2019;294(21):8529\u201342. https:\/\/doi.org\/10.1074\/jbc.RA118.004361.","journal-title":"J Biol Chem"},{"issue":"2","key":"35_CR122","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3945\/jn.115.216580","volume":"146","author":"OI Selmin","year":"2016","unstructured":"Selmin OI, Fang C, Lyon AM, Doetschman TC, Thompson PA, Martinez JD, et al. Inactivation of adenomatous polyposis coli reduces bile acid\/farnesoid X receptor expression through FXR gene CpG methylation in mouse colon tumors and human colon cancer cells. J Nutr. 2016;146(2):236\u201342. https:\/\/doi.org\/10.3945\/jn.115.216580.","journal-title":"J Nutr"},{"issue":"10","key":"35_CR123","doi-asserted-by":"publisher","first-page":"6507","DOI":"10.1074\/jbc.M114.620369","volume":"290","author":"F Yang","year":"2015","unstructured":"Yang F, Hu Y, Liu HX, Wan YJ. MiR-22-silenced cyclin a expression in colon and liver cancer cells is regulated by bile acid receptor. J Biol Chem. 2015;290(10):6507\u201315. https:\/\/doi.org\/10.1074\/jbc.M114.620369.","journal-title":"J Biol Chem"},{"issue":"10","key":"35_CR124","doi-asserted-by":"publisher","first-page":"e48461","DOI":"10.1371\/journal.pone.0048461","volume":"7","author":"Z Peng","year":"2012","unstructured":"Peng Z, Raufman JP, Xie G. Src-mediated cross-talk between farnesoid X and epidermal growth factor receptors inhibits human intestinal cell proliferation and tumorigenesis. PLoS One. 2012;7(10):e48461. https:\/\/doi.org\/10.1371\/journal.pone.0048461.","journal-title":"PLoS One"},{"issue":"10","key":"35_CR125","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1002\/ijc.26293","volume":"130","author":"S Lax","year":"2012","unstructured":"Lax S, Schauer G, Prein K, Kapitan M, Silbert D, Berghold A, et al. Expression of the nuclear bile acid receptor\/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis. Int J Cancer. 2012;130(10):2232\u20139. https:\/\/doi.org\/10.1002\/ijc.26293.","journal-title":"Int J Cancer"},{"issue":"23","key":"35_CR126","doi-asserted-by":"publisher","first-page":"9589","DOI":"10.1158\/0008-5472.CAN-08-1791","volume":"68","author":"S Modica","year":"2008","unstructured":"Modica S, Murzilli S, Salvatore L, Schmidt DR, Moschetta A. Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res. 2008;68(23):9589\u201394. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1791.","journal-title":"Cancer Res"},{"issue":"6","key":"35_CR127","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1023\/b:ddas.0000034558.78747.98","volume":"49","author":"A De Gottardi","year":"2004","unstructured":"De Gottardi A, Touri F, Maurer CA, Perez A, Maurhofer O, Ventre G, et al. The bile acid nuclear receptor FXR and the bile acid-binding protein IBABP are differently expressed in colon cancer. Dig Dis Sci. 2004;49(6):982\u20139. https:\/\/doi.org\/10.1023\/b:ddas.0000034558.78747.98.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"35_CR128","doi-asserted-by":"publisher","first-page":"7617","DOI":"10.3892\/ol.2018.8342","volume":"15","author":"H Zhou","year":"2018","unstructured":"Zhou H, Ni Z, Li T, Su L, Zhang L, Liu N, et al. Activation of FXR promotes intestinal metaplasia of gastric cells via SHP-dependent upregulation of the expression of CDX2. Oncol Lett. 2018;15(5):7617\u201324. https:\/\/doi.org\/10.3892\/ol.2018.8342.","journal-title":"Oncol Lett"},{"issue":"2","key":"35_CR129","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1124\/jpet.108.145409","volume":"328","author":"RR Maran","year":"2009","unstructured":"Maran RR, Thomas A, Roth M, Sheng Z, Esterly N, Pinson D, et al. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther. 2009;328(2):469\u201377. https:\/\/doi.org\/10.1124\/jpet.108.145409.","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"35_CR130","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1002\/cncr.27910","volume":"119","author":"B Guan","year":"2013","unstructured":"Guan B, Li H, Yang Z, Hoque A, Xu X. Inhibition of farnesoid X receptor controls esophageal cancer cell growth in vitro and in nude mouse xenografts. Cancer. 2013;119(7):1321\u20139. https:\/\/doi.org\/10.1002\/cncr.27910.","journal-title":"Cancer."},{"issue":"2","key":"35_CR131","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1042\/BJ20102096","volume":"438","author":"F Lian","year":"2011","unstructured":"Lian F, Xing X, Yuan G, Sch\u00e4fer C, Rauser S, Walch A, et al. Farnesoid X receptor protects human and murine gastric epithelial cells against inflammation-induced damage. Biochem J. 2011;438(2):315\u201323. https:\/\/doi.org\/10.1042\/BJ20102096.","journal-title":"Biochem J"},{"issue":"10","key":"35_CR132","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1002\/ijc.27915","volume":"132","author":"S Catalano","year":"2013","unstructured":"Catalano S, Panza S, Malivindi R, Giordano C, Barone I, Bossi G, et al. Inhibition of Leydig tumor growth by farnesoid X receptor activation: the in vitro and in vivo basis for a novel therapeutic strategy. Int J Cancer. 2013;132(10):2237\u201347. https:\/\/doi.org\/10.1002\/ijc.27915.","journal-title":"Int J Cancer"},{"issue":"7","key":"35_CR133","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/carcin\/bgx050","volume":"38","author":"L Valanejad","year":"2017","unstructured":"Valanejad L, Lewis K, Wright M, Jiang Y, D'Souza A, Karns R, et al. FXR-gankyrin axis is involved in development of pediatric liver cancer. Carcinogenesis. 2017;38(7):738\u201347. https:\/\/doi.org\/10.1093\/carcin\/bgx050.","journal-title":"Carcinogenesis."},{"issue":"2","key":"35_CR134","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.bbrc.2016.04.106","volume":"474","author":"X Huang","year":"2016","unstructured":"Huang X, Zeng Y, Wang X, Ma X, Li Q, Li N, et al. FXR blocks the growth of liver cancer cells through inhibiting mTOR-s6K pathway. Biochem Biophys Res Commun. 2016;474(2):351\u20136. https:\/\/doi.org\/10.1016\/j.bbrc.2016.04.106.","journal-title":"Biochem Biophys Res Commun"},{"issue":"33","key":"35_CR135","doi-asserted-by":"publisher","first-page":"34606","DOI":"10.18632\/oncotarget.5314","volume":"6","author":"F Guo","year":"2015","unstructured":"Guo F, Xu Z, Zhang Y, Jiang P, Huang G, Chen S, et al. FXR induces SOCS3 and suppresses hepatocellular carcinoma. Oncotarget. 2015;6(33):34606\u201316. https:\/\/doi.org\/10.18632\/oncotarget.5314.","journal-title":"Oncotarget"},{"issue":"10","key":"35_CR136","doi-asserted-by":"publisher","first-page":"e43044","DOI":"10.1371\/journal.pone.0043044","volume":"7","author":"U Deuschle","year":"2012","unstructured":"Deuschle U, Sch\u00fcler J, Schulz A, Schl\u00fcter T, Kinzel O, Abel U, et al. FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. PLoS One. 2012;7(10):e43044. https:\/\/doi.org\/10.1371\/journal.pone.0043044.","journal-title":"PLoS One"},{"issue":"1","key":"35_CR137","doi-asserted-by":"publisher","first-page":"12502","DOI":"10.1038\/s41598-017-12629-4","volume":"7","author":"YM Attia","year":"2017","unstructured":"Attia YM, Tawfiq RA, Ali AA, Elmazar MM. The FXR agonist, obeticholic acid, suppresses HCC proliferation & metastasis: role of IL-6\/STAT3 signalling pathway. Sci Rep. 2017;7(1):12502. https:\/\/doi.org\/10.1038\/s41598-017-12629-4.","journal-title":"Sci Rep"},{"issue":"3","key":"35_CR138","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/hep.26146","volume":"57","author":"Y Jiang","year":"2013","unstructured":"Jiang Y, Iakova P, Jin J, Sullivan E, Sharin V, Hong IH, et al. Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer. Hepatology. 2013;57(3):1098\u2013106. https:\/\/doi.org\/10.1002\/hep.26146.","journal-title":"Hepatology."},{"issue":"2","key":"35_CR139","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1210\/me.2011-1157","volume":"26","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Ge X, Heemstra LA, Chen WD, Xu J, Smith JL, et al. Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in Ob\/Ob mice. Mol Endocrinol. 2012;26(2):272\u201380. https:\/\/doi.org\/10.1210\/me.2011-1157.","journal-title":"Mol Endocrinol"},{"issue":"10","key":"35_CR140","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.bbamcr.2013.05.006","volume":"1833","author":"J Vaquero","year":"2013","unstructured":"Vaquero J, Briz O, Herraez E, Muntan\u00e9 J, Marin JJ. Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds. Biochim Biophys Acta. 2013;1833(10):2212\u20139. https:\/\/doi.org\/10.1016\/j.bbamcr.2013.05.006.","journal-title":"Biochim Biophys Acta"},{"issue":"17","key":"35_CR141","doi-asserted-by":"publisher","first-page":"24005","DOI":"10.18632\/oncotarget.8209","volume":"7","author":"KY Ng","year":"2016","unstructured":"Ng KY, Chai S, Tong M, Guan XY, Lin CH, Ching YP, et al. C-terminal truncated hepatitis B virus X protein promotes hepatocellular carcinogenesis through induction of cancer and stem cell-like properties. Oncotarget. 2016;7(17):24005\u201317. https:\/\/doi.org\/10.18632\/oncotarget.8209.","journal-title":"Oncotarget"},{"issue":"11","key":"35_CR142","doi-asserted-by":"publisher","first-page":"G1245","DOI":"10.1152\/ajpgi.00439.2011","volume":"303","author":"H Su","year":"2012","unstructured":"Su H, Ma C, Liu J, Li N, Gao M, Huang A, et al. Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteristics in human hepatocellular carcinoma. Am J Physiol Gastrointest Liver Physiol. 2012;303(11):G1245\u201353. https:\/\/doi.org\/10.1152\/ajpgi.00439.2011.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"35_CR143","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12943-015-0427-9","volume":"14","author":"J He","year":"2015","unstructured":"He J, Zhao K, Zheng L, Xu Z, Gong W, Chen S, et al. Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells. Mol Cancer. 2015;14:163. https:\/\/doi.org\/10.1186\/s12943-015-0427-9.","journal-title":"Mol Cancer"},{"issue":"2","key":"35_CR144","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.taap.2013.06.016","volume":"272","author":"G Li","year":"2013","unstructured":"Li G, Kong B, Zhu Y, Zhan L, Williams JA, Tawfik O, et al. Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice. Toxicol Appl Pharmacol. 2013;272(2):299\u2013305. https:\/\/doi.org\/10.1016\/j.taap.2013.06.016.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"35_CR145","doi-asserted-by":"publisher","first-page":"11203","DOI":"10.1038\/s41598-017-11549-7","volume":"7","author":"M Cariello","year":"2017","unstructured":"Cariello M, Peres C, Zerlotin R, Porru E, Sabb\u00e0 C, Roda A, et al. Long-term administration of nuclear bile acid receptor FXR agonist prevents spontaneous hepatocarcinogenesis in Abcb4\u2212\/\u2212 mice. Sci Rep. 2017;7(1):11203. https:\/\/doi.org\/10.1038\/s41598-017-11549-7.","journal-title":"Sci Rep"},{"issue":"5","key":"35_CR146","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1210\/me.2011-1383","volume":"26","author":"N Liu","year":"2012","unstructured":"Liu N, Meng Z, Lou G, Zhou W, Wang X, Zhang Y, et al. Hepatocarcinogenesis in FXR\u2212\/\u2212 mice mimics human HCC progression that operates through HNF1\u03b1 regulation of FXR expression. Mol Endocrinol. 2012;26(5):775\u201385. https:\/\/doi.org\/10.1210\/me.2011-1383.","journal-title":"Mol Endocrinol"},{"issue":"1","key":"35_CR147","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1124\/jpet.111.179390","volume":"338","author":"A Wolfe","year":"2011","unstructured":"Wolfe A, Thomas A, Edwards G, Jaseja R, Guo GL, Apte U. Increased activation of the Wnt\/\u03b2-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J Pharmacol Exp Ther. 2011;338(1):12\u201321. https:\/\/doi.org\/10.1124\/jpet.111.179390.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"35_CR148","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.18632\/oncotarget.2899","volume":"6","author":"X Liu","year":"2015","unstructured":"Liu X, Zhang X, Ji L, Gu J, Zhou M, Chen S. Farnesoid X receptor associates with \u03b2-catenin and inhibits its activity in hepatocellular carcinoma. Oncotarget. 2015;6(6):4226\u201338. https:\/\/doi.org\/10.18632\/oncotarget.2899.","journal-title":"Oncotarget"},{"issue":"11","key":"35_CR149","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/ijc.29312","volume":"136","author":"U Deuschle","year":"2015","unstructured":"Deuschle U, Birkel M, Hambruch E, Hornberger M, Kinzel O, Perovi\u0107-Ottstadt S, et al. The nuclear bile acid receptor FXR controls the liver-derived tumor suppressor histidine-rich glycoprotein. Int J Cancer. 2015;136(11):2693\u2013704. https:\/\/doi.org\/10.1002\/ijc.29312.","journal-title":"Int J Cancer"},{"issue":"4","key":"35_CR150","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1002\/hep.26187","volume":"57","author":"Y Chen","year":"2013","unstructured":"Chen Y, Song X, Valanejad L, Vasilenko A, More V, Qiu X, et al. Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma. Hepatology. 2013;57(4):1530\u201341. https:\/\/doi.org\/10.1002\/hep.26187.","journal-title":"Hepatology."},{"issue":"6","key":"35_CR151","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/jb\/mvs101","volume":"152","author":"T Fujino","year":"2012","unstructured":"Fujino T, Takeuchi A, Maruko-Ohtake A, Ohtake Y, Satoh J, Kobayashi T, et al. Critical role of farnesoid X receptor for hepatocellular carcinoma cell proliferation. J Biochem. 2012;152(6):577\u201386. https:\/\/doi.org\/10.1093\/jb\/mvs101.","journal-title":"J Biochem"},{"issue":"5","key":"35_CR152","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.jhep.2012.06.016","volume":"57","author":"Z Meng","year":"2012","unstructured":"Meng Z, Wang X, Gan Y, Zhang Y, Zhou H, Ness CV, et al. Deletion of IFN\u03b3 enhances hepatocarcinogenesis in FXR knockout mice. J Hepatol. 2012;57(5):1004\u201312. https:\/\/doi.org\/10.1016\/j.jhep.2012.06.016.","journal-title":"J Hepatol"},{"issue":"5","key":"35_CR153","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/carcin\/bgl249","volume":"28","author":"I Kim","year":"2007","unstructured":"Kim I, Morimura K, Shah Y, Yang Q, Ward JM, Gonzalez FJ. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis. 2007;28(5):940\u20136. https:\/\/doi.org\/10.1093\/carcin\/bgl249.","journal-title":"Carcinogenesis."},{"issue":"1","key":"35_CR154","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41598-017-00698-4","volume":"7","author":"W You","year":"2017","unstructured":"You W, Chen B, Liu X, Xue S, Qin H, Jiang H. Farnesoid X receptor, a novel proto-oncogene in non-small cell lung cancer, promotes tumor growth via directly transactivating CCND1. Sci Rep. 2017;7(1):591. https:\/\/doi.org\/10.1038\/s41598-017-00698-4.","journal-title":"Sci Rep"},{"issue":"6","key":"35_CR155","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/bjc.2011.37","volume":"104","author":"JY Lee","year":"2011","unstructured":"Lee JY, Lee KT, Lee JK, Lee KH, Jang KT, Heo JS, et al. Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion. Br J Cancer. 2011;104(6):1027\u201337. https:\/\/doi.org\/10.1038\/bjc.2011.37.","journal-title":"Br J Cancer"},{"issue":"20","key":"35_CR156","doi-asserted-by":"publisher","first-page":"33265","DOI":"10.18632\/oncotarget.16633","volume":"8","author":"H Hu","year":"2017","unstructured":"Hu H, Wu LL, Han T, Zhuo M, Lei W, Cui JJ, et al. Correlated high expression of FXR and Sp1 in cancer cells confers a poor prognosis for pancreatic cancer: a study based on TCGA and tissue microarray. Oncotarget. 2017;8(20):33265\u201375. https:\/\/doi.org\/10.18632\/oncotarget.16633.","journal-title":"Oncotarget"},{"issue":"7","key":"35_CR157","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.molonc.2016.04.007","volume":"10","author":"S Joshi","year":"2016","unstructured":"Joshi S, Cruz E, Rachagani S, Guha S, Brand RE, Ponnusamy MP, et al. Bile acids-mediated overexpression of MUC4 via FAK-dependent c-Jun activation in pancreatic cancer. Mol Oncol. 2016;10(7):1063\u201377. https:\/\/doi.org\/10.1016\/j.molonc.2016.04.007.","journal-title":"Mol Oncol"},{"issue":"6","key":"35_CR158","first-page":"2111","volume":"12","author":"XL Chen","year":"2019","unstructured":"Chen XL, Xie KX, Yang ZL, Yuan LW. Expression of FXR and HRG and their clinicopathological significance in benign and malignant pancreatic lesions. Int J Clin Exp Pathol. 2019;12(6):2111\u201320.","journal-title":"Int J Clin Exp Pathol"},{"issue":"4","key":"35_CR159","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3892\/etm.2014.1894","volume":"8","author":"J Liu","year":"2014","unstructured":"Liu J, Tong SJ, Wang X, Qu LX. Farnesoid X receptor inhibits LNcaP cell proliferation via the upregulation of PTEN. Exp Ther Med. 2014;8(4):1209\u201312. https:\/\/doi.org\/10.3892\/etm.2014.1894.","journal-title":"Exp Ther Med"},{"issue":"2","key":"35_CR160","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1042\/BJ20071136","volume":"410","author":"J Kaeding","year":"2008","unstructured":"Kaeding J, Bouchaert E, B\u00e9langer J, Caron P, Chouinard S, Verreault M, et al. Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells. Biochem J. 2008;410(2):245\u201353. https:\/\/doi.org\/10.1042\/BJ20071136.","journal-title":"Biochem J"},{"issue":"1","key":"35_CR161","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2131\/jts.45.25","volume":"45","author":"T Fujino","year":"2020","unstructured":"Fujino T, Sugizaki K, Kato R, Beppu M, Murakami S, Lee H, et al. Farnesoid X receptor and liver X receptors regulate Oct3\/4 expression by multiple feedback regulating system in normal renal-derived cells and renal adenocarcinoma cells. J Toxicol Sci. 2020;45(1):25\u201335. https:\/\/doi.org\/10.2131\/jts.45.25.","journal-title":"J Toxicol Sci"},{"issue":"3","key":"35_CR162","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1016\/j.clbc.2017.07.013","volume":"18","author":"KK Thakur","year":"2018","unstructured":"Thakur KK, Bordoloi D, Kunnumakkara AB. Alarming burden of triple-negative breast cancer in India. Clin Breast Cancer. 2018;18(3):e393\u20139. https:\/\/doi.org\/10.1016\/j.clbc.2017.07.013.","journal-title":"Clin Breast Cancer"},{"issue":"8","key":"35_CR163","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.3390\/ijms19082362","volume":"19","author":"AM Ranaware","year":"2018","unstructured":"Ranaware AM, Banik K, Deshpande V, Padmavathi G, Roy NK, Sethi G, et al. Magnolol: a neolignan from the Magnolia family for the prevention and treatment of cancer. Int J Mol Sci. 2018;19(8):2362. https:\/\/doi.org\/10.3390\/ijms19082362.","journal-title":"Int J Mol Sci"},{"key":"35_CR164","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bpobgyn.2019.11.006","volume":"65","author":"MA Thorat","year":"2020","unstructured":"Thorat MA, Balasubramanian R. Breast cancer prevention in high-risk women. Best Pract Res Clin Obstet Gynaecol. 2020;65:18\u201331. https:\/\/doi.org\/10.1016\/j.bpobgyn.2019.11.006.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"4","key":"35_CR165","doi-asserted-by":"publisher","first-page":"633","DOI":"10.4149\/neo_2017_420","volume":"64","author":"C Giaginis","year":"2017","unstructured":"Giaginis C, Karandrea D, Alexandrou P, Giannopoulou I, Tsourouflis G, Troungos C, et al. High farnesoid X receptor (FXR) expression is a strong and independent prognosticator in invasive breast carcinoma. Neoplasma. 2017;64(4):633\u20139. https:\/\/doi.org\/10.4149\/neo_2017_420.","journal-title":"Neoplasma."},{"key":"35_CR166","doi-asserted-by":"crossref","unstructured":"Bordoloi D, Banik K, Khwairakpam AD, Sharma A, Monisha J, Sailo BL, et al. Different approaches to overcome chemoresistance in esophageal cancer. Cancer Cell Chemoresist Chemosensitization. 2018;241.","DOI":"10.1142\/9789813208575_0010"},{"issue":"34","key":"35_CR167","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.3748\/wjg.v19.i34.5598","volume":"19","author":"Y Zhang","year":"2013","unstructured":"Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19(34):5598\u2013606. https:\/\/doi.org\/10.3748\/wjg.v19.i34.5598.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"35_CR168","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1053\/j.gastro.2013.08.008","volume":"145","author":"J Matsuzaki","year":"2013","unstructured":"Matsuzaki J, Suzuki H, Tsugawa H, Watanabe M, Hossain S, Arai E, et al. Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis. Gastroenterology. 2013;145(6):1300\u201311. https:\/\/doi.org\/10.1053\/j.gastro.2013.08.008.","journal-title":"Gastroenterology."},{"key":"35_CR169","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1476-4598-5-48","volume":"5","author":"A De Gottardi","year":"2006","unstructured":"De Gottardi A, Dumonceau JM, Bruttin F, Vonlaufen A, Morard I, Spahr L, et al. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro. Mol Cancer. 2006;5:48. https:\/\/doi.org\/10.1186\/1476-4598-5-48.","journal-title":"Mol Cancer"},{"issue":"38","key":"35_CR170","doi-asserted-by":"publisher","first-page":"61021","DOI":"10.18632\/oncotarget.10477","volume":"7","author":"A Carino","year":"2016","unstructured":"Carino A, Graziosi L, D'Amore C, Cipriani S, Marchian\u00f2 S, Marino E, et al. The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines. Oncotarget. 2016;7(38):61021\u201335. https:\/\/doi.org\/10.18632\/oncotarget.10477.","journal-title":"Oncotarget"},{"key":"35_CR171","doi-asserted-by":"crossref","unstructured":"Choudhary H, Bordoloi D, Prakash J, Manteghi N, Padmavathi G, Monisha J, et al. Different chemosensitization approaches in gastric cancer. Cancer Cell Chemoresist Chemosensit. 2018:267\u2013319.","DOI":"10.1142\/9789813208575_0011"},{"issue":"12","key":"35_CR172","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3390\/biom9120836","volume":"9","author":"D Bordoloi","year":"2019","unstructured":"Bordoloi D, Banik K, Padmavathi G, Vikkurthi R, Harsha C, Roy NK, et al. TIPE2 induced the proliferation, survival, and migration of lung cancer cells through modulation of Akt\/mTOR\/NF-\u03baB signaling cascade. Biomolecules. 2019;9(12):836. https:\/\/doi.org\/10.3390\/biom9120836.","journal-title":"Biomolecules."},{"key":"35_CR173","doi-asserted-by":"publisher","first-page":"118475","DOI":"10.1016\/j.lfs.2020.118475","volume":"262","author":"D Bordoloi","year":"2020","unstructured":"Bordoloi D, Banik K, Vikkurthi R, Thakur KK, Padmavathi G, Sailo BL, et al. Inflection of Akt\/mTOR\/STAT-3 cascade in TNF-\u03b1 induced protein 8 mediated human lung carcinogenesis. Life Sci. 2020;262:118475. https:\/\/doi.org\/10.1016\/j.lfs.2020.118475.","journal-title":"Life Sci"},{"issue":"2","key":"35_CR174","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ijc.25041","volume":"127","author":"KB Harikumar","year":"2010","unstructured":"Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, Pandey MK, et al. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer. 2010;127(2):257\u201368. https:\/\/doi.org\/10.1002\/ijc.25041.","journal-title":"Int J Cancer"},{"issue":"3","key":"35_CR175","doi-asserted-by":"publisher","first-page":"E292","DOI":"10.1002\/ijc.26442","volume":"131","author":"AB Kunnumakkara","year":"2012","unstructured":"Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, Dey S, et al. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets. Int J Cancer. 2012;131(3):E292\u2013303. https:\/\/doi.org\/10.1002\/ijc.26442.","journal-title":"Int J Cancer"},{"issue":"14","key":"35_CR176","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-08-0024","volume":"14","author":"N Dhillon","year":"2008","unstructured":"Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14(14):4491\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0024.","journal-title":"Clin Cancer Res"},{"issue":"44","key":"35_CR177","doi-asserted-by":"publisher","first-page":"9694","DOI":"10.3748\/wjg.v22.i44.9694","volume":"22","author":"M Ilic","year":"2016","unstructured":"Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694\u2013705. https:\/\/doi.org\/10.3748\/wjg.v22.i44.9694.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"35_CR178","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-06-4257","volume":"67","author":"AB Kunnumakkara","year":"2007","unstructured":"Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res. 2007;67(8):3853\u201361. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4257.","journal-title":"Cancer Res"},{"issue":"21","key":"35_CR179","doi-asserted-by":"publisher","first-page":"8695","DOI":"10.1158\/0008-5472.CAN-10-2318","volume":"70","author":"AB Kunnumakkara","year":"2010","unstructured":"Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, Dey S, et al. {gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment. Cancer Res. 2010;70(21):8695\u2013705. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2318.","journal-title":"Cancer Res"},{"issue":"5","key":"35_CR180","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1007\/s13277-013-0825-9","volume":"34","author":"S Yang","year":"2013","unstructured":"Yang S, Lee KT, Lee JY, Lee JK, Lee KH, Rhee JC. Inhibition of SCAMP1 suppresses cell migration and invasion in human pancreatic and gallbladder cancer cells. Tumour Biol. 2013;34(5):2731\u20139. https:\/\/doi.org\/10.1007\/s13277-013-0825-9.","journal-title":"Tumour Biol"},{"issue":"2","key":"35_CR181","doi-asserted-by":"publisher","first-page":"332","DOI":"10.4149\/neo_2015_040","volume":"62","author":"C Giaginis","year":"2015","unstructured":"Giaginis C, Koutsounas I, Alexandrou P, Zizi-Serbetzoglou A, Patsouris E, Kouraklis G, et al. Elevated farnesoid X receptor (FXR) and retinoid X receptors (RXRs) expression is associated with less tumor aggressiveness and favourable prognosis in patients with pancreatic adenocarcinoma. Neoplasma. 2015;62(2):332\u201341. https:\/\/doi.org\/10.4149\/neo_2015_040.","journal-title":"Neoplasma."},{"issue":"10021","key":"35_CR182","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","volume":"387","author":"U Capitanio","year":"2016","unstructured":"Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387(10021):894\u2013906. https:\/\/doi.org\/10.1016\/S0140-6736(15)00046-X.","journal-title":"Lancet."},{"issue":"4","key":"35_CR183","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3390\/molecules24040734","volume":"24","author":"S Girisa","year":"2019","unstructured":"Girisa S, Shabnam B, Monisha J, Fan L, Halim CE, Arfuso F, et al. Potential of zerumbone as an anti-cancer agent. Molecules. 2019;24(4):734. https:\/\/doi.org\/10.3390\/molecules24040734.","journal-title":"Molecules."},{"key":"35_CR184","first-page":"S187","volume-title":"Virchows Archiv","author":"S Theocharis","year":"2018","unstructured":"Theocharis S, Masaoutis C, Giaginis C, Liapis G, Mitropoulos D, Constantinides C, et al. Clinical significance of farnesoid X receptor expression in renal cell carcinoma. In: Virchows Archiv, vol. 473. New York: SPRINGER; 2018. p. S187."},{"issue":"3","key":"35_CR185","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2131\/jts.42.259","volume":"42","author":"T Fujino","year":"2017","unstructured":"Fujino T, Sakamaki R, Ito H, Furusato Y, Sakamoto N, Oshima T, et al. Farnesoid X receptor regulates the growth of renal adenocarcinoma cells without affecting that of a normal renal cell-derived cell line. J Toxicol Sci. 2017;42(3):259\u201365. https:\/\/doi.org\/10.2131\/jts.42.259.","journal-title":"J Toxicol Sci"},{"issue":"1","key":"35_CR186","doi-asserted-by":"publisher","first-page":"G48","DOI":"10.1152\/ajpgi.00234.2013","volume":"306","author":"AM Bailey","year":"2014","unstructured":"Bailey AM, Zhan L, Maru D, Shureiqi I, Pickering CR, Kiriakova G, et al. FXR silencing in human colon cancer by DNA methylation and KRAS signaling. Am J Physiol Gastrointest Liver Physiol. 2014;306(1):G48\u201358. https:\/\/doi.org\/10.1152\/ajpgi.00234.2013.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"12","key":"35_CR187","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1007\/s12094-015-1436-2","volume":"17","author":"M Benavides","year":"2015","unstructured":"Benavides M, Anton A, Gallego J, G\u00f3mez MA, Jimenez-Gordo A, La Casta A, et al. Biliary tract cancers: SEOM clinical guidelines. Clin Transl Oncol. 2015;17(12):982\u20137. https:\/\/doi.org\/10.1007\/s12094-015-1436-2.","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"35_CR188","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/13651820801992641","volume":"10","author":"SA Khan","year":"2008","unstructured":"Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford). 2008;10(2):77\u201382. https:\/\/doi.org\/10.1080\/13651820801992641.","journal-title":"HPB (Oxford)"},{"issue":"1","key":"35_CR189","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/1541-7786.MCR-13-0503","volume":"12","author":"E Lozano","year":"2014","unstructured":"Lozano E, Sanchez-Vicente L, Monte MJ, Herraez E, Briz O, Banales JM, et al. Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. Mol Cancer Res. 2014;12(1):91\u2013100. https:\/\/doi.org\/10.1158\/1541-7786.MCR-13-0503.","journal-title":"Mol Cancer Res"},{"issue":"14","key":"35_CR190","first-page":"2637","volume":"127","author":"W Wang","year":"2014","unstructured":"Wang W, Yin X, Li G, Yi J, Wang J. Expressions of farnesoid X receptor and myeloid cell leukemia sequence 1 protein are associated with poor prognosis in patients with gallbladder cancer. Chin Med J. 2014;127(14):2637\u201342.","journal-title":"Chin Med J"},{"issue":"2","key":"35_CR191","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/jcp.29080","volume":"235","author":"H Wang","year":"2020","unstructured":"Wang H, Zhan M, Liu Q, Wang J. Glycochenodeoxycholate promotes the metastasis of gallbladder cancer cells by inducing epithelial to mesenchymal transition via activation of SOCS3\/JAK2\/STAT3 signaling pathway. J Cell Physiol. 2020;235(2):1615\u201323. https:\/\/doi.org\/10.1002\/jcp.29080.","journal-title":"J Cell Physiol"},{"issue":"1 Suppl","key":"35_CR192","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/1097-0142(19950101)75:1+<203::aid-cncr2820751308>3.0.co;2-v","volume":"75","author":"HD Dorfman","year":"1995","unstructured":"Dorfman HD, Czerniak B. Bone cancers. Cancer. 1995;75(1 Suppl):203\u201310. https:\/\/doi.org\/10.1002\/1097-0142(19950101)75:1+<203::aid-cncr2820751308>3.0.co;2-v.","journal-title":"Cancer."},{"issue":"8","key":"35_CR193","doi-asserted-by":"publisher","first-page":"RA177","DOI":"10.12659\/msm.881893","volume":"17","author":"X Dai","year":"2011","unstructured":"Dai X, Ma W, He X, Jha RK. Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Med Sci Monit. 2011;17(8):RA177\u201390. https:\/\/doi.org\/10.12659\/msm.881893.","journal-title":"Med Sci Monit"},{"key":"35_CR194","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fphar.2017.00150","volume":"8","author":"FR Evola","year":"2017","unstructured":"Evola FR, Costarella L, Pavone V, Caff G, Cannav\u00f2 L, Sessa A, et al. Biomarkers of osteosarcoma, chondrosarcoma, and Ewing sarcoma. Front Pharmacol. 2017;8:150. https:\/\/doi.org\/10.3389\/fphar.2017.00150.","journal-title":"Front Pharmacol"},{"key":"35_CR195","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1142\/9789813208575_0004","volume-title":"Mechanism of chemoresistance in bone cancer and different chemosensitization approaches. Cancer cell chemoresistance and chemosensitization","author":"G Padmavathi","year":"2018","unstructured":"Padmavathi G, Bordoloi D, Banik K, Javadi M, Singh AK, Kunnumakkara AB. Mechanism of chemoresistance in bone cancer and different chemosensitization approaches. Cancer cell chemoresistance and chemosensitization. Singapore: World Scientific; 2018. p. 81\u2013106."},{"issue":"4","key":"35_CR196","first-page":"205","volume":"98","author":"JL Ferguson","year":"2018","unstructured":"Ferguson JL, Turner SP. Bone cancer: diagnosis and treatment principles. Am Fam Physician. 2018;98(4):205\u201313.","journal-title":"Am Fam Physician"},{"issue":"11","key":"35_CR197","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1111\/bph.13621","volume":"174","author":"AB Kunnumakkara","year":"2017","unstructured":"Kunnumakkara AB, Bordoloi D, Padmavathi G, Monisha J, Roy NK, Prasad S, et al. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol. 2017;174(11):1325\u201348. https:\/\/doi.org\/10.1111\/bph.13621.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"35_CR198","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/nu11030704","volume":"11","author":"C Buhrmann","year":"2019","unstructured":"Buhrmann C, Yazdi M, Popper B, Kunnumakkara AB, Aggarwal BB, Shakibaei M. Induction of the epithelial-to-mesenchymal transition of human colorectal cancer by human TNF-\u03b2 (lymphotoxin) and its reversal by resveratrol. Nutrients. 2019;11(3):704. https:\/\/doi.org\/10.3390\/nu11030704.","journal-title":"Nutrients."},{"key":"35_CR199","doi-asserted-by":"publisher","first-page":"104635","DOI":"10.1016\/j.phrs.2020.104635","volume":"153","author":"K Banik","year":"2020","unstructured":"Banik K, Ranaware AM, Harsha C, Nitesh T, Girisa S, Deshpande V, et al. Piceatannol: a natural stilbene for the prevention and treatment of cancer. Pharmacol Res. 2020;153:104635. https:\/\/doi.org\/10.1016\/j.phrs.2020.104635.","journal-title":"Pharmacol Res"},{"issue":"7","key":"35_CR200","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.3390\/ijms21072393","volume":"21","author":"C Buhrmann","year":"2020","unstructured":"Buhrmann C, Kunnumakkara AB, Popper B, Majeed M, Aggarwal BB, Shakibaei M. Calebin a potentiates the effect of 5-FU and TNF-\u03b2 (Lymphotoxin \u03b1) against human colorectal cancer cells: potential role of NF-\u03baB. Int J Mol Sci. 2020;21(7):2393. https:\/\/doi.org\/10.3390\/ijms21072393.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"35_CR201","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3390\/biomedicines8080236","volume":"8","author":"C Buhrmann","year":"2020","unstructured":"Buhrmann C, Shayan P, Banik K, Kunnumakkara AB, Kubatka P, Koklesova L, et al. Targeting NF-\u03baB signaling by Calebin a, a compound of turmeric, in multicellular tumor microenvironment: potential role of apoptosis induction in crc cells. Biomedicines. 2020;8(8):236. https:\/\/doi.org\/10.3390\/biomedicines8080236.","journal-title":"Biomedicines."},{"key":"35_CR202","doi-asserted-by":"publisher","unstructured":"Ahmed M. Colon Cancer: A clinician's perspective in 2019. Gastroenterology Res. 2020;13(1):1\u201310. doi:https:\/\/doi.org\/10.14740\/gr1239.","DOI":"10.14740\/gr1239"},{"issue":"2","key":"35_CR203","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/MIB.0b013e318286ff2e","volume":"19","author":"J Torres","year":"2013","unstructured":"Torres J, Bao X, Iuga AC, Chen A, Harpaz N, Ullman T, et al. Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia. Inflamm Bowel Dis. 2013;19(2):275\u201382. https:\/\/doi.org\/10.1097\/MIB.0b013e318286ff2e.","journal-title":"Inflamm Bowel Dis"},{"issue":"38","key":"35_CR204","doi-asserted-by":"publisher","first-page":"63665","DOI":"10.18632\/oncotarget.18885","volume":"8","author":"L Cao","year":"2017","unstructured":"Cao L, Che Y, Meng T, Deng S, Zhang J, Zhao M, et al. Repression of intestinal transporters and FXR-FGF15 signaling explains bile acids dysregulation in experimental colitis-associated colon cancer. Oncotarget. 2017;8(38):63665\u201379. https:\/\/doi.org\/10.18632\/oncotarget.18885.","journal-title":"Oncotarget"},{"issue":"8","key":"35_CR205","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41419-020-02819-w","volume":"11","author":"J Yu","year":"2020","unstructured":"Yu J, Li S, Guo J, Xu Z, Zheng J, Sun X. Farnesoid X receptor antagonizes Wnt\/\u03b2-catenin signaling in colorectal tumorigenesis. Cell Death Dis. 2020;11(8):640. https:\/\/doi.org\/10.1038\/s41419-020-02819-w.","journal-title":"Cell Death Dis"},{"issue":"5","key":"35_CR206","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.phrs.2012.07.005","volume":"66","author":"P Martinez-Becerra","year":"2012","unstructured":"Martinez-Becerra P, Monte I, Romero MR, Serrano MA, Vaquero J, Macias RI, et al. Up-regulation of FXR isoforms is not required for stimulation of the expression of genes involved in the lack of response of colon cancer to chemotherapy. Pharmacol Res. 2012;66(5):419\u201327. https:\/\/doi.org\/10.1016\/j.phrs.2012.07.005.","journal-title":"Pharmacol Res"},{"issue":"11","key":"35_CR207","doi-asserted-by":"publisher","first-page":"G1044","DOI":"10.1152\/ajpgi.00297.2015","volume":"310","author":"R Krattinger","year":"2016","unstructured":"Krattinger R, Bostr\u00f6m A, Schi\u00f6th HB, Thasler WE, Mwinyi J, Kullak-Ublick GA. microRNA-192 suppresses the expression of the farnesoid X receptor. Am J Physiol Gastrointest Liver Physiol. 2016;310(11):G1044\u201351. https:\/\/doi.org\/10.1152\/ajpgi.00297.2015.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"9","key":"35_CR208","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1021\/mp300178a","volume":"9","author":"E Herraez","year":"2012","unstructured":"Herraez E, Gonzalez-Sanchez E, Vaquero J, Romero MR, Serrano MA, Marin JJ, et al. Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins. Mol Pharm. 2012;9(9):2565\u201376. https:\/\/doi.org\/10.1021\/mp300178a.","journal-title":"Mol Pharm"},{"issue":"1","key":"35_CR209","doi-asserted-by":"publisher","first-page":"188314","DOI":"10.1016\/j.bbcan.2019.188314","volume":"2020","author":"D Anwanwan","year":"1873","unstructured":"Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 1873;2020(1):188314. https:\/\/doi.org\/10.1016\/j.bbcan.2019.188314.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"35_CR210","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.phrs.2018.04.021","volume":"133","author":"AD Khwairakpam","year":"2018","unstructured":"Khwairakpam AD, Bordoloi D, Thakur KK, Monisha J, Arfuso F, Sethi G, et al. Possible use of Punica granatum (pomegranate) in cancer therapy. Pharmacol Res. 2018;133:53\u201364. https:\/\/doi.org\/10.1016\/j.phrs.2018.04.021.","journal-title":"Pharmacol Res"},{"issue":"1","key":"35_CR211","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41467-019-14050-z","volume":"11","author":"B Losic","year":"2020","unstructured":"Losic B, Craig AJ, Villacorta-Martin C, Martins-Filho SN, Akers N, Chen X, et al. Intratumoral heterogeneity and clonal evolution in liver cancer. Nat Commun. 2020;11(1):291. https:\/\/doi.org\/10.1038\/s41467-019-14050-z.","journal-title":"Nat Commun"},{"issue":"1","key":"35_CR212","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/aps.2014.117","volume":"36","author":"XF Huang","year":"2015","unstructured":"Huang XF, Zhao WY, Huang WD. FXR and liver carcinogenesis. Acta Pharmacol Sin. 2015;36(1):37\u201343. https:\/\/doi.org\/10.1038\/aps.2014.117.","journal-title":"Acta Pharmacol Sin"},{"issue":"42","key":"35_CR213","doi-asserted-by":"publisher","first-page":"29749","DOI":"10.1074\/jbc.274.42.29749","volume":"274","author":"J Grober","year":"1999","unstructured":"Grober J, Zaghini I, Fujii H, Jones SA, Kliewer SA, Willson TM, et al. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor\/9-cis-retinoic acid receptor heterodimer. J Biol Chem. 1999;274(42):29749\u201354. https:\/\/doi.org\/10.1074\/jbc.274.42.29749.","journal-title":"J Biol Chem"},{"issue":"1","key":"35_CR214","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40139-012-0003-6","volume":"1","author":"X Wang","year":"2013","unstructured":"Wang X, Fu X, Van Ness C, Meng Z, Ma X, Huang W. Bile acid receptors and liver cancer. Curr Pathobiol Rep. 2013;1(1):29\u201335. https:\/\/doi.org\/10.1007\/s40139-012-0003-6.","journal-title":"Curr Pathobiol Rep"},{"key":"35_CR215","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.5604\/01.3001.0010.5501","volume":"16","author":"A Di Ciaula","year":"2017","unstructured":"Di Ciaula A, Wang DQ, Molina-Molina E, Baccetto RL, Calamita G, Palmieri VO, et al. Bile acids and cancer: direct and environmental-dependent effects. Ann Hepatol. 2017;16:S87\u2013105. https:\/\/doi.org\/10.5604\/01.3001.0010.5501.","journal-title":"Ann Hepatol"},{"issue":"9","key":"35_CR216","doi-asserted-by":"publisher","first-page":"e1007954","DOI":"10.1371\/journal.ppat.1007954","volume":"15","author":"B Jia","year":"2019","unstructured":"Jia B, Jeon CO. Promotion and induction of liver cancer by gut microbiome-mediated modulation of bile acids. PLoS Pathog. 2019;15(9):e1007954. https:\/\/doi.org\/10.1371\/journal.ppat.1007954.","journal-title":"PLoS Pathog"},{"key":"35_CR217","doi-asserted-by":"publisher","unstructured":"Patton ME, Kelekar S, Taylor LJ, Thakare R, Lee S, Alnouti Y, et al. Circulating bile acid levels direct sex-differences in liver cancer development, bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.06.25.172635.","DOI":"10.1101\/2020.06.25.172635"},{"issue":"3","key":"35_CR218","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.biochi.2012.06.022","volume":"95","author":"M Baptissart","year":"2013","unstructured":"Baptissart M, Vega A, Maqdasy S, Caira F, Baron S, Lobaccaro JM, et al. Bile acids: from digestion to cancers. Biochimie. 2013;95(3):504\u201317. https:\/\/doi.org\/10.1016\/j.biochi.2012.06.022.","journal-title":"Biochimie."},{"issue":"21","key":"35_CR219","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1101\/gad.1978810","volume":"24","author":"J Cai","year":"2010","unstructured":"Cai J, Zhang N, Zheng Y, De Wilde RF, Maitra A, Pan D. The hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. 2010;24(21):2383\u20138. https:\/\/doi.org\/10.1101\/gad.1978810.","journal-title":"Genes Dev"},{"issue":"3","key":"35_CR220","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","volume":"67","author":"F Yang","year":"2007","unstructured":"Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007;67(3):863\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1078.","journal-title":"Cancer Res"},{"issue":"5","key":"35_CR221","doi-asserted-by":"publisher","first-page":"G295","DOI":"10.1152\/ajpgi.00134.2015","volume":"310","author":"B Kong","year":"2016","unstructured":"Kong B, Zhu Y, Li G, Williams JA, Buckley K, Tawfik O, et al. Mice with hepatocyte-specific FXR deficiency are resistant to spontaneous but susceptible to cholic acid-induced hepatocarcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2016;310(5):G295\u2013302. https:\/\/doi.org\/10.1152\/ajpgi.00134.2015.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"35_CR222","doi-asserted-by":"publisher","first-page":"118182","DOI":"10.1016\/j.lfs.2020.118182","volume":"260","author":"D Parama","year":"2020","unstructured":"Parama D, Boruah M, Yachna K, Rana V, Banik K, Harsha C, et al. Diosgenin, a steroidal saponin, and its analogs: effective therapies against different chronic diseases. Life Sci. 2020;260:118182. https:\/\/doi.org\/10.1016\/j.lfs.2020.118182.","journal-title":"Life Sci"},{"issue":"10","key":"35_CR223","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1158\/1940-6207.CAPR-10-0136","volume":"4","author":"JV Heymach","year":"2011","unstructured":"Heymach JV, Shackleford TJ, Tran HT, Yoo SY, Do KA, Wergin M, et al. Effect of low-fat diets on plasma levels of NF-\u03baB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila). 2011;4(10):1590\u20138. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-10-0136.","journal-title":"Cancer Prev Res (Phila)"},{"key":"35_CR224","doi-asserted-by":"publisher","first-page":"102860","DOI":"10.1016\/j.critrevonc.2019.102860","volume":"145","author":"J Wang","year":"2020","unstructured":"Wang J, Ni J, Beretov J, Thompson J, Graham P, Li Y. Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer. Crit Rev Oncol Hematol. 2020;145:102860. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.102860.","journal-title":"Crit Rev Oncol Hematol"},{"key":"35_CR225","doi-asserted-by":"publisher","first-page":"109679","DOI":"10.1016\/j.biopha.2019.109679","volume":"121","author":"R Xu","year":"2020","unstructured":"Xu R, Hu J. The role of JNK in prostate cancer progression and therapeutic strategies. Biomed Pharmacother. 2020;121:109679. https:\/\/doi.org\/10.1016\/j.biopha.2019.109679.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"35_CR226","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/pros.20899","volume":"69","author":"SB Muralimanoharan","year":"2009","unstructured":"Muralimanoharan SB, Kunnumakkara AB, Shylesh B, Kulkarni KH, Haiyan X, Ming H, et al. Butanol fraction containing berberine or related compound from nexrutine inhibits NFkappaB signaling and induces apoptosis in prostate cancer cells. Prostate. 2009;69(5):494\u2013504. https:\/\/doi.org\/10.1002\/pros.20899.","journal-title":"Prostate."},{"key":"35_CR227","doi-asserted-by":"publisher","first-page":"968040","DOI":"10.1155\/2012\/968040","volume":"2012","author":"S Sikka","year":"2012","unstructured":"Sikka S, Chen L, Sethi G, Kumar AP. Targeting PPAR\u03b3 signaling cascade for the prevention and treatment of prostate cancer. PPAR Res. 2012;2012:968040. https:\/\/doi.org\/10.1155\/2012\/968040.","journal-title":"PPAR Res"},{"issue":"23","key":"35_CR228","doi-asserted-by":"publisher","first-page":"6963","DOI":"10.1158\/0008-5472.CAN-13-1462","volume":"73","author":"L Grosse","year":"2013","unstructured":"Grosse L, P\u00e2quet S, Caron P, Fazli L, Rennie PS, B\u00e9langer A, et al. Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications. Cancer Res. 2013;73(23):6963\u201371. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1462.","journal-title":"Cancer Res"},{"key":"35_CR229","doi-asserted-by":"publisher","first-page":"155076291880107","DOI":"10.1177\/1550762918801070","volume":"15","author":"M Cariello","year":"2018","unstructured":"Cariello M, Ducheix S, Maqdasy S, Baron S, Moschetta A, Lobaccaro JA. LXRs, SHP, and FXR in prostate cancer: enemies or m\u00e9nage \u00e0 quatre with AR? Nucl Recept Signal. 2018;15:1550762918801070. https:\/\/doi.org\/10.1177\/1550762918801070.","journal-title":"Nucl Recept Signal"},{"issue":"11","key":"35_CR230","first-page":"5118","volume":"8","author":"N Liu","year":"2016","unstructured":"Liu N, Zhao J, Wang J, Teng H, Fu Y, Yuan H. Farnesoid X receptor ligand CDCA suppresses human prostate cancer cells growth by inhibiting lipid metabolism via targeting sterol response element binding protein 1. Am J Transl Res. 2016;8(11):5118\u201324.","journal-title":"Am J Transl Res"},{"issue":"8","key":"35_CR231","doi-asserted-by":"publisher","first-page":"5581","DOI":"10.1074\/jbc.M109.052670","volume":"285","author":"S Catalano","year":"2010","unstructured":"Catalano S, Malivindi R, Giordano C, Gu G, Panza S, Bonofiglio D, et al. Farnesoid X receptor, through the binding with steroidogenic factor 1-responsive element, inhibits aromatase expression in tumor Leydig cells. J Biol Chem. 2010;285(8):5581\u201393. https:\/\/doi.org\/10.1074\/jbc.M109.052670.","journal-title":"J Biol Chem"},{"issue":"20","key":"35_CR232","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.2217\/fon-2017-0090","volume":"13","author":"C Giaginis","year":"2017","unstructured":"Giaginis C, Tsoukalas N, Alexandrou P, Tsourouflis G, Dana E, Delladetsima I, et al. Clinical significance of farnesoid X receptor expression in thyroid neoplasia. Future Oncol. 2017;13(20):1785\u201392. https:\/\/doi.org\/10.2217\/fon-2017-0090.","journal-title":"Future Oncol"},{"issue":"3","key":"35_CR233","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/cld.861","volume":"15","author":"JYL Chiang","year":"2020","unstructured":"Chiang JYL, Ferrell JM. Bile acid biology, pathophysiology, and therapeutics. Clin Liver Dis (Hoboken). 2020;15(3):91\u20134. https:\/\/doi.org\/10.1002\/cld.861.","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"6","key":"35_CR234","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.tranon.2018.08.015","volume":"11","author":"B Shabnam","year":"2018","unstructured":"Shabnam B, Padmavathi G, Banik K, Girisa S, Monisha J, Sethi G, et al. Sorcin a potential molecular target for cancer therapy. Transl Oncol. 2018;11(6):1379\u201389. https:\/\/doi.org\/10.1016\/j.tranon.2018.08.015.","journal-title":"Transl Oncol"},{"key":"35_CR235","first-page":"1","volume-title":"Next generation point-of-care biomedical sensors Technologies for Cancer Diagnosis","author":"G Padmavathi","year":"2017","unstructured":"Padmavathi G, Bordoloi D, Banik K, Kunnumakkara AB. Cancer biomarkers: important tools for cancer diagnosis and prognosis. In: Next generation point-of-care biomedical sensors Technologies for Cancer Diagnosis. Singapore: Springer; 2017. p. 1\u201329."},{"key":"35_CR236","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.phrs.2019.04.004","volume":"144","author":"K Banik","year":"2019","unstructured":"Banik K, Ranaware AM, Deshpande V, Nalawade SP, Padmavathi G, Bordoloi D, et al. Honokiol for cancer therapeutics: a traditional medicine that can modulate multiple oncogenic targets. Pharmacol Res. 2019;144:192\u2013209. https:\/\/doi.org\/10.1016\/j.phrs.2019.04.004.","journal-title":"Pharmacol Res"},{"key":"35_CR237","doi-asserted-by":"publisher","first-page":"313","DOI":"10.37349\/etat.2020.00019","volume":"1","author":"S Girisa","year":"2020","unstructured":"Girisa S, Parama D, Harsha C, Banik K, Kunnumakkara AB. Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer. Explor Target Antitumor Ther. 2020;1:313\u201342. https:\/\/doi.org\/10.37349\/etat.2020.00019.","journal-title":"Explor Target Antitumor Ther"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-021-00035-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-021-00035-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-021-00035-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T23:27:04Z","timestamp":1625873224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-021-00035-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,10]]},"references-count":237,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["35"],"URL":"https:\/\/doi.org\/10.1186\/s43556-021-00035-2","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,10]]},"assertion":[{"value":"18 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Corresponding author Ajaikumar B. Kunnumakkara is a member of the Editorial Board for Molecular Biomedicine, Ajaikumar B. Kunnumakkara was not involved in the journal's review of, or decisions related to, this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}